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ABSTRACT 
 
IMPACT OF ANTI-VIRAL IMMUNITY ON NEURAL STEM/PROGENITOR CELL  
ACTIVITY AND IMPLICATIONS FOR CNS DEVELOPMENT 
 
 
 
By 
Apurva Kulkarni 
August 2017 
 
Dissertation supervised by Lauren A. O’Donnell 
Viral infection and inflammation in the central nervous system (CNS) can cause 
neuropathology, particularly in the prenatal and neonatal stages. Severe damage to the CNS may 
result from cytopathic effects of viral infection or from the immune response that may lyse virally-
infected cells or release inflammatory mediators to mediate viral clearance. Neural stem/progenitor 
cells (NPSCs) are multipotent cells in the CNS that are often disrupted by neurotropic viral 
infections. They may be directly infected by the virus or respond to inflammatory cytokines 
released from resident as well as infiltrating immune cells.  This bystander effect may affect NSPC 
differentiation and proliferation depending on the milieu of inflammatory mediators. Interferon 
gamma (IFN), a potent antiviral cytokine required for the control and clearance of many CNS 
infections, can differentially affect cell survival and cell cycle progression depending upon the cell 
type and the profile of activated intracellular signaling molecules.  Here, we show that IFN 
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inhibits proliferation of primary NSPCs through dephosphorylation of the tumor suppressor 
Retinoblastoma protein (pRb), which is dependent on activation of Signal Transducers and 
Activators of Transcription-1 (STAT1) signaling pathways. We observed inhibition of 
proliferation in wild type NSPCs (WT/NSPCs) as well as a decrease in neurosphere growth. IFN 
restricted cell cycle progression by inhibiting the G1- to S-phase transition. Cell cycle restriction 
was associated with decreases in the G1–phase specific cyclin E/CDK2 proteins and in pRb 
phosphorylation at serine 795 (S795). Together, these results indicate that the NSPC cell cycle was 
restricted in the late G1-phase. In STAT1-deficient (STAT1-KO) NSPCs, the effects of IFN on 
NSPC proliferation were lost, demonstrating that IFN signaling is STAT1-dependent. These data 
define a mechanism by which IFN could contribute to a reduction in NSPC proliferation in 
inflammatory conditions.  Furthermore, this was the first study to implicate the pRb protein in 
mediating anti-proliferative effects of IFN  on NSPCs. 
The cellular tropism of neurotropic viruses varies, with NSPCs being targeted by some viruses and 
spared by others. During a viral infection, microglia are typically the first immune cells to become 
activated in the brain.   Microglia may contribute to the anti-viral program generated against the 
virus and/or alter other neural cells through the release of inflammatory mediators.  Evidence in 
neonatal brains suggest that microglia can also influence NSPC numbers and differentiation under 
basal conditions.  However, whether microglia affect NSPCs during an anti-viral immune response 
is an outstanding question.  To evaluate the effects of microglial activation on NSPCs, we used a 
mouse model for measles virus (MV) infection in neurons. In this model, MV infection is restricted 
to mature CNS neurons expressing the human isoform of CD46, a receptor for MV.  NSPCs and 
microglia are spared from infection.  In order to examine the interactions between infected neurons, 
microglia, and NSPCs, primary microglia were co-cultured with MV-infected CD46+ neurons and 
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the conditioned medium was used to treat primary NSPCs in culture.  We found that factors 
released from the infected neuron/microglia co-cultures increased BrdU-incorporation and 
neuronal differentiation in NSPCs.  Thus, even though the NSPCs are not infected in this model, 
the cells respond by generating young neurons that could serve as potential replacements for the 
mature neurons damaged by the virus.   These studies provide a novel model system for identifying 
the signals that microglia use to communicate between infected neurons and responding NSPCs. 
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Chapter 1: Literature Review 
I. NSPCs in the CNS 
Neural stem cells are stem cells of the nervous system that can self-renew and generate 
both neurons and glia.  They can self-renew and proliferate without limit, to produce 
progeny cells which terminally differentiate into neurons, astrocytes and oligodendrocytes. 
The term ‘progenitor cell’ to refers to the cells that can proliferate and differentiate into 
more than one cell type. Neural progenitor cells can therefore be unipotent, bipotent, or 
multipotent. A distinguishing feature of neural progenitor cells is that, unlike a stem cell, 
it has a limited proliferative ability and does not exhibit self-renewal. For the purpose of 
this study we will refer to them collectively as neural stem/progenitor cells (NSPCs), which 
are the only multipotent population of cells in the CNS. Together, these cells bring about 
normal CNS development in the embryo where they populate the CNS broadly, while their 
anatomical localization becomes restricted as the brain matures1,2. 
 
NSPCs in developing and adult CNS 
CNS development begins with the differentiation of neuroepithelial cells (NECs) 
from the ectodermal layer. These cells line the cerebral ventricles early in embryonic 
development. NECs switch from symmetric to asymmetric division, which results in the 
generation of committed progenitor cells. Cortical neurogenesis begins around embryonic 
day (E) 9–10 in the mouse, and neuroepithelial cells at this stage acquire features associated 
with glial cells, called radial glial (RG) cells3. Formation of the cortical layers and 
thickening of the cortex increases the length of the pial-directed radial processes of RG.  
These processes are formed as result of extensive cytoskeletal changes in the radial glia, 
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and ultimately serve as scaffolds to direct newly born neurons to the edge of the cortex. 
The RG express a number of glial markers such as astrocyte-specific glutamate transporter 
(GLAST) and brain lipid-binding protein (BLBP)4. Like neuroepithelial cells, RG cells 
maintain apical-basal polarity, line the lateral ventricles, and undergo interkinetic nuclear 
migration, thereby maintaining a pseudostratified epithelium within the ventricular zone. 
A unique characteristic of RG cells is the interkinetic nuclear migration seen in different 
phases of the cell cycle. Nuclei undergoing S phase of the cell cycle form a layer several 
cell-body diameters from the ventricle, at the apical side of the VZ, while nuclei in M-
phase line up along the surface of the ventricle, and nuclei in G1 and G2 phases are 
transitioning between the S and M phases in the mid-region5. The function of this 
phenomenon is still not clear. Regardless, RG either generate daughter neurons directly or 
produce a second, more restricted intermediate progenitor cells (IPCs), also referred to as 
a basal progenitor cell, which populates the embryonic subventricular zone (SVZ)6.  
As CNS development proceeds, the number of NSPCs progressively declines. In 
mice at E10.5, NSPCs amount to about 50% of the total cell number. This number declines 
to about 1% on postnatal day 1 (P1).  A small population of NSPCs persists in specific 
niches in the adult brain, namely within the SVZ and the subgranular zone (SGZ) of the 
dentate gyrus (DG)1,7,8.  The SVZ is located along the lateral wall of the lateral ventricle.  
NSPCs in the SVZ differentiate into neuroblasts that migrate along the rostral migratory 
stream into the olfactory bulb. In the olfactory bulb, these neuroblasts terminally 
differentiate into granule and periglomerular neurons9. NSPCs in the SGZ of the DG give 
rise to granule neurons, which are important in learning and memory10. However, the 
number of NSPCs in the adult SVZ are limited and therefore, for the purposes of this study, 
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NSPCs were derived from mouse E12.5 cortical tissue. Adult neurogenesis from the SGZ 
is affected in many pathologies such as epilepsy and mood-related disorders. Natural aging 
and age-related neurodegenerative diseases may also result in changes in neurogenesis11. 
Comparative studies  between embryonic, neonatal, and adult SVZ-derived NSPCs showed 
that these cells significantly differ in their gene expression profiles12.   The authors found 
changes in gene expression patterns in NSPCs from E13, E17, and adult SVZ NSPCs. As 
an example, the expression pattern of the neurogenic and gliogenic genes followed a 
specific pattern. At mid gestation (E13), neurogenic genes were highly expressed. This 
expression went down in late gestation (E17) and increased in the adult SVZ. During mid-
gestation, genes that induce gliogenesis were highly expressed. Moreover, NSPCs at 
different ages differ in their proliferative potential and differentiation owing the differences 
in their gene expression profiles and epigenetic differences13. Considering that these cells 
change in their gene expression profiles at different ages, how age-dependent changes in 
these cells contribute to disease progression at different stages of development needs to be 
studied. 
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Table 1 
Virus CNS pathology 
Cytomegalovirus Deafness, encephalitis, epilepsy, blindness 
Herpes Simplex Virus Encephalitis, blindness, herptic neuralgia 
Zika Virus Microcephaly, agyria  
Lymphocytic choriomeningitis virus Developmental deficits, hydrocephalus 
West Nile Virus Encephalitis, meningitis, myopathy, 
paralysis 
Human Immunodeficiency virus Dementia, loss of motor function, 
encephalitis, myelitis 
Borna Disease Virus  Schizophrenia, depression  
Measles Virus Encephalitis (ADME, SSPE, MIBE)  
Japanese Encephalitis Virus Seizures, acute flaccid paralysis 
Coxsackie B virus Epilepsy 
Varicella Zoster Virus Vasculopathy of small and large cerebral 
vessels.  
 Table 1: Neurotropic Viruses and associated neuropathologies. 
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II. Viral infections in the CNS 
 Among the 61 known viral families, twelve families are known to infect the CNS. 
There is a substantial diversity in the neurotropic mechanisms of these viruses14. In the 
human host, they may enter the CNS by blood and cerebrospinal fluid (CSF) or within 
infected leukocytes. The neuropathologic manifestations of most viral infections depend 
on the specific virus, the age and immune status of the patient, and the coexistence of other 
neurologic diseases and infections altering the blood-brain barrier. The characteristic 
neuropathologies of some of the viruses relevant to this study are briefly described here 
and summarized in Table 1. 
 
Human Cytomegalovirus (HCMV) 
HCMV is a double stranded DNA virus (dsDNA) and belongs to the herpesviridae 
family. In adults, HMCV is observed in immunocompromised patients, and most 
commonly in acquired immunodeficiency syndrome (AIDS) patients.  HCMV-induced 
neurological disorders  include longitudinal extensive transverse myelitis and encephalitis 
and subcortical dementia15. HCMV neuropathology may manifest as encephalitis with 
microglial nodules frequently associated with cytomegalic cells or as necrotizing 
ventriculoencephalitis with intranuclear inclusion bodies. Congenital CMV infections are 
a major cause of birth defects in the US, with approximately 0.5% newborns infected by 
transplacental transfer from the mother16. Ten to fifteen percent of these infections develop 
neurological sequelae such as hearing loss, mental impairments, and microcephaly17. Thus, 
the developing brain is especially susceptible to the pathogenic effects of CMV infection. 
Imaging studies in developing fetuses reveal major structural abnormalities including focal 
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necrosis, astrogliosis, calcifications and brain atrophy. Similar abnormalities were also 
found in infected neonates. HCMV has shown tropism towards all cell types in the brain.  
In vitro studies have shown that CMV could infect microvascular endothelial cells, 
astrocytes, neurons, microglia and NSPCs. Primary postnatal astrocyte cultures show 
CMV-induced cytopathic cell death. In the CNS, CMV infection in the astrocytes induced 
apoptotic cell death when infection was at its peak. This could be possibly to allow for 
completion of viral replication cycle18. NSPCs also are permissible to HCMV infection. 
HCMV induces apoptosis in NSPCs through the activation of endoplasmic reticulum stress 
and mitochondrial dysfunction, which may partially explain the brain atrophy observed in 
many cases of HCMV infection. 
 
Herpes Simplex Virus-1 (HSV-1) 
HSV-1, also a dsDNA virus belonging to the herpesviridae family, infects approximately 
67% of adults in the USA19.  In most cases, the virus resides latently in sensory neurons of 
the trigeminal ganglion with intermittent bouts of reactivation19.  During reactivation, new 
infectious viral particles are produced that travel down the axon and infect epithelial cells 
at the site of neuronal innervation, leading to the typical lesions associated with HSV-1.  
However, in some cases, HSV-1 may spread from the trigeminal ganglia to the temporal 
and inferior frontal lobes to establish a more severe, widespread CNS infection. The viral 
particles can be detected both in cytoplasm and nucleus of the infected neurons, astrocytes, 
and oligodendrocytes. The virus spreads via cell-to-cell contact and cytolytic cell death is 
observed in infected cells20. Apoptotic neuronal and glial death was observed in patients 
with acute viral CNS infection, specifically in patients with herpes simplex encephalitis21. 
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The resultant herpes simplex encephalitis (HSE) can be fatal or cause long-term cognitive 
deficits.  The factors that lead to HSE and unrestricted HSV-1 spread in the brain are 
unknown. However, genetic factors including deficits in the type I interferons, have been 
implicated22.  
 
Zika Virus (ZIKV) 
 ZIKV is a single-stranded RNA (ssRNA) virus belonging to the Flaviviridae 
family, which includes other mosquito-borne viruses such as Dengue Virus and 
Chikungunya virus.  The  first human cases of ZIKV infections were detected in Uganda 
and Tanzania in 1952, with the presence of neutralizing antibodies in human sera23. 
Significant interest and research has been carried out on the neurological sequelae associate 
with ZIKV after the 2015 outbreak in the American continent. Prior to this, sporadic 
outbreaks were reported in humans on the Yap Island in the Federated State of Micronesia 
in 2007 and French Polynesia in 2013–2014. However, in Brazil, a 20-fold increase in 
microcephaly prevalence in neonates indicated a possible role of ZIKV infection during 
pregnancy24.  The virus enters the human host after they are bitten by a mosquito vector 
(Aedes aegypti or Aedes albopictus). Infections in human adults are often asymptomatic or 
associated with mild illness, but the virus can cross the placenta and cause severe harm to 
the fetus.  Recently, conclusive evidence was found that ZIKV infection in pregnant 
mothers was directly associated with neurological defects in neonates25.  ZIKV was found 
in the amniotic fluid of pregnant mothers and in brains of aborted fetuses. ZIKV-associated 
neuropathology was found to be mainly microcephaly but also included agyria, 
calcifications in the cortex and subcortical white matter, and ventriculomegaly26.  Studies 
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have focused on the mechanisms through which the ZIKV may be causing these CNS 
pathologies. ZIKV is known to infect human NSPCs as well as astrocytes27.  Of importance 
are the mechanisms of NSPC infection and consequences on CNS development. 
 
West Nile Virus (WNV)  
Also, a member of the Flaviviridae family, WNV is known to have sporadic 
outbreaks in the world28. On average, one in 140 infected individuals may develop 
meningoencephalitis, but the prevalence increases in the older population29. Patients with 
West Nile encephalitis (WNE) may also develop coarse tremors, particularly in the upper 
extremities. Other symptoms include weakness in either or all the limbs and acute flaccid 
paralysis30. In FVB/N mice that are susceptible to WNV disease and mortality, it was also 
observed that WNV could cross the placenta during early gestation but not late gestation31. 
The first human case of transuterine WNV transfer showed elevated levels of IgM 
antibodies. Elevated fetal IgM signifies prepartum infection in the newborn because IgM 
cannot cross the placental barrier and must be produced de novo by the fetus. The neonate 
also had severe chorioretinal and CNS malformations32. A larger study in WNV-infected 
mothers found that only one of the 55 neonates born were found to have anti-WNV IgM, 
suggesting that WNV does not commonly cross the placental barrier. However, many of 
the fetuses had varying degrees of neurological sequelae including microcephaly and 
lissencephaly, suggesting that the maternal immune response against the infection may 
have an impact on neurodevelopment33. Moreover, WNV can cause severe damage in 
neonates whether the virus is acquired before or after delivery. Therefore, it is important to 
study the mechanisms through which WNV may affect both the adult and developing CNS.  
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Japanese Encephalitis Virus (JEV) 
JEV is another a member of the Flaviviridae family that is associate with 
neurological disease. JEV is endemic in South and Southeast Asia and transmitted to 
humans by mosquito bites 34. Transplacental transmission of the virus has also been 
observed35.  The virus spreads from the skin to other organs (kidney, liver, and spleen) and 
subsequently crosses the blood-brain barrier to enter the CNS. Severe encephalitis has been 
associated with JEV infections, which ultimately results in neuropathologies include 
poliomyelitis-like flaccid paralysis36. Severe seizures are common in children in up to 85% 
JEV-infected children34. To understand the immune mediated pathology in vivo, an 
intranasal JEV infection induced encephalitis model in macaques was used. Infiltration of 
CD4+ and CD8+ T-cells caused vascular damage and blood brain barrier (BBB) leakage.  
Neurons are the predominant target of JEV in the brain, and infected neurons are often 
surrounded by activated microglia. Although astrocytic infection is not observed, 
macrophage infiltration along with astrocyte and microglia activation are seen near sites of 
infection37.  In JEV brains, both infected and uninfected neurons undergo apoptotic cell 
death37. This finding suggests that mechanisms other than JEV infection, such as immune-
mediated cytotoxicity could also contribute to neuropathology.  
 
Borna Disease Virus (BDV) 
Bornaviruses belong to the family Bornaviridae, which are a family of negative 
sense RNA viruses.  The prototypical mammalian Bornavirus-1,  (BDV), causes a typically 
fatal neurological disease in horses and sheep38. There is ample evidence of BDV-induced 
encephalitis and resulting behavioral changes in experimental animals such as rats, mice, 
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and tree shrews39. The role of BDV in human neuropathology is controversial. A lack of 
reliable diagnostic tools for BDV in humans further complicates studies into BDV-
dependent neuropathologies.  Nevertheless, studies have shown presence of BDV RNA in 
human subjects with known behavioral deficits and hippocampal pathology40. Serologic 
and molecular epidemiologic evidence suggest that BDV may also be associated with 
neuropsychiatric disorders41. For example, a subset of psychiatric patients with either 
unipolar depression or biopolar disorder tested positive for BDV by detection of BDV-
specific antibodies41. These studies have relied on antibody titers, indirect 
immunofluorescence, and qRT-PCR measurements, which can be prone to artifacts and 
false positives.  Thus, although there is significant interest in understanding the 
contribution of BDV to neurological disorders, the field is currently hampered by 
challenges in specific detection of the virus in human samples and a lack of 
epidemiological data.   
 
Measles Virus (MV) 
MV is a negative sense RNA virus and a member of the Paramyxoviridae family. 
It has been the a major cause of deaths in the developing world with an estimated 122,000 
deaths in 201242.  Upon exposure to respiratory droplets, the virus enters the upper 
respiratory tract and is taken up by dendritic cells, B cells, and T cells expressing the 
CD150 receptor43. MV infection in the CNS, although rare, can cause severe neurological 
disorders: primary measles encephalitis (PME), measles inclusion body encephalitis 
(MIBE), and subacute sclerosing panencephalitis (SSPE). PME occurs concurrently with 
primary measles infection.  Measles inclusion body encephalitis (MIBE) occurs in 
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immunosuppressed individuals 3–6 months following an acute MV infection. These cases 
occur in patients who are immunosuppressed (HIV infection) or those on 
immunosuppressive therapy44. SSPE can manifest 4–10 years following acute MV 
infection with a frequency of approximately one in 1700 to one in 330045. The 
neuropathology of SSPE is characterized by extensive infection of predominantly neurons 
and oligodendrocytes throughout the brain including the frontal cortex, occipital cortex, 
basal ganglia, thalamus pons, medulla and parietal cortex46. Presence of viral antigen  in 
astrocytes and infiltrating macrophages has also been reported in SSPE patients47.  The 
delay between primary infection and CNS disease is not understood in SSPE, but 
hypotheses include a potential latent phase of viral replication in the brain, or a slow 
progression of the virus through CNS tissue via transynatic spread.  Regardless, because 
MV infection typically occurs in the first two years of life, MV-associated CNS disease is 
found almost exclusively in young children.   
 
III. Effects of antiviral immunity on NSPC activity 
 The above viral neurotropic infections have diverse mechanisms of infection and 
neuropathology at different ages. Neurotropic viruses may damage CNS tissue by a 
cytopathic effect, where infected cells are killed directly by the virus, or because of the 
immune response to the virally-infected cells48.  In addition to neurons, NSPCs are also 
altered during viral CNS infections.  NSPCs are permissible to several viruses including 
murine and human cytomegalovirus, herpes simplex virus, Japanese encephalitic virus, and 
Zika virus49-52.  These infections result in reduced NSPC proliferation and increased 
apoptosis, which could impair neurogenesis, neuronal development, and neural repair51,52.   
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In this section, we discuss the interactions between specific viruses and NSPCs.  A 
summary of the aforementioned viruses and their effects on NSPC activity is described in 
Table 2. 
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Table 2 
Virus Immune response Effect on NSPCs 
Herpes simplex 
Virus  
• Infiltration of peripheral macrophages, 
CD8+ T-cells and neutrophils into the 
CNS leading to increased mortality 
independent of viral load53 
• Microglial activation caused IL-6/STAT3-
mediated increase in neuronal 
differentiation54 
• NSPC, astrocytes, neurons 
infected 
•  Decreased NSPC proliferation 
• Increased glial differentiation 
• Less infection in the neuronal 
pool 
• IFN dependent effects 
Cytomegalovirus • CD8+ T-cell infiltration: major source of 
IFN; Essential for viral control 
• IFN increased MHC I and II expression 
on NSPCs. CMV decreased IFN-induced 
MHCI expression  
• Activation of infected microglia. 
Increased IL-6 and TNF secretion55 
• NSPCs are primarily infected 
• ER stress-mediated decrease in 
NSPC proliferation, survival, and 
neuronal differentiation56 
• Possible viral evasion from 
immune system and IFN57 
•  Persistent infection 
Zika Virus  • Increased secretion of proinflammatory 
cytokines in embryonic brain 
• Increased cytokine levels in maternal 
amniotic fluid58 
• Infection and persistence in 
NSPCs and radial glia 
• Decreased pool and survival in 
these cells59 
Measles Virus • Increased CD4+ and CD8+ T-cell 
infiltration. Critical for viral control 60 
• IFN-mediated viral control on neurons61 
• Decreased immature neuron 
pool62 
• No evidence of NSPC infection62 
Borna disease 
virus  
• CD4+ and CD8+ infiltration into the CNS. 
CD8+ T-cells associated with 
neurotoxicity leading to neuronal loss in 
the hippocampus63 
• Increased microglial activation and 
associated MHC I, MHCII and IL-6 
expression 
• Direct NSPC infection 
• No change in NSPC survival and 
proliferation 
• Decreased neuronal 
differentiation64 
Table 2: Neurotropic viruses and immune-mediated changes in NSPC activity. 
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Herpes simplex virus-1 
NSPCs, astrocytes, young and mature neurons are all permissible to HSV-1 infection65.  
In vivo studies involving nasal HSV-1 inoculation in mice implicate two mechanisms of 
damage to the CNS.  First is the infection and lysis of neurons that control critical 
physiological functions66.  In addition, Lundberg et al showed that the anti-viral immune 
response against HSV-1 played a major role in CNS pathology67.  In this study, mice 
susceptible to HSV-1 developed fatal focal lesions in the brain that consisted on infiltrating 
macrophages and neutrophils.  When the macrophages and neutrophils were depleted, the 
mice showed delayed mortality as compared to non-depleted animals. Moreover, treatment 
with acyclovir decreased viral load to undetectable levels, but did not reduce mortality.  
Therefore, these studies show that the inflammatory response in the brain contributes to 
pathology and death in HSV-1 infected mice.  
Studies using intranasal delivery of HSV to the brain also demonstrate an initial 
increase in NSPC numbers during the acute phase (6 days post-infection; dpi) of HSV 
infection. However, NSPC numbers decline during the chronic phase (10-30 dpi), wherein 
the adaptive immune response is active68. The NSPCs are not infected by HSV-1 in the 
intranasal model, suggesting that changes in NSPC function are due to the inflammatory 
environment.  However, in vitro NSPC cultures derived from induced pluripotent stem 
cells (iPSCs) were permissible to HSV-1 infections and demonstrated HSV-1 mediated cell 
lysis69. Chucair-Elliott and colleagues observed that intraocular HSV-1 inoculation in 
C57/BL6 mice resulted in infection and loss of nestin+ NSPCs in the SVZ. Moreover, 8 
days post-infection, the NSPC pool in the SVZ of these animals was depleted. In vitro 
cultures of NSPCs from C57/BL6 mice were susceptible to HSV-1 infection and resulted 
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in NSPC cell loss. The number of doublecortin+ (DCX+) immature neurons also declined, 
which was associated with a loss in cell survival and not as a result of deceased 
differentiation. The discrepancy in results between Chucair-Elliott et al and Rotschafer et 
al could be because differences in viral (Syn 17+ v/s McRae) or mouse (Balb/c v/s 
C57BL6) strains used. Surprisingly, co-culture with microglia prevented this loss, which 
suggests that microglia may play a neuroprotective role for immature neurons. Treatment 
with conditioned medium from NSPC-microglia co-cultures alleviated neuronal loss in an 
IL-6/STAT3 dependent manner. This study also looked at the effects of microglial 
activation during HSV-1 infection on NSPC activity. Treatment with conditioned medium 
from HSV-1 infected NSPCs caused decreased neuronal differentiation 54. Together, these 
studies suggest that NSPCs are affected by both viral infections and the immune response 
to it, and microglial cells play an important role in mediating the effects of the immune 
response.  
 
Cytomegalovirus (CMV) 
CMV preferentially targets NSPCs in brain tissue, leading to apoptosis of infected cells 
and inhibition of proliferation and neurogenesis56. These observations have been made both 
in human NSPCs and in mouse models of murine CMV (mCMV) infection51,70. Studies 
with hCMV also show that, when infected, human NSPCs undergo apoptosis due to 
improper folding of proteins in the endoplasmic reticulum (ER), triggering the ER stress 
response56.  These observations indicate that CMV not only inhibits NSPC function but 
also results in cell death. Moreover, Rolland et al observed that hCMV infection decreased 
neuronal differentation in embryonic stem cell-derived NSPCs. hCMV infection led to 
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increased Peroxisome Proliferator-Activated Receptor gamma (PPAR)  activation in 
NSPCs.  Importantly, hCMV-mediated PPAR activation was seen in both uninfected and 
infected cells, suggesting that the infected NSPCs released soluble factors that resulted in 
PPAR activation in other cells in the vicinity. This observation of a bystander effect was 
confirmed by treating uninfected NSPCs with virus-free supernatants from infected 
cultures, which produced a similar induction of PPAR. Upon further evaluation, this 
soluble mediator was found to be the PPAR agonist 9-hydroxyoctadecadienoic acid (9-
HODE) Many studies have shown that mCMV infection of NSPCs induced apoptosis in 
the cells 56,70. In the developing brain, NPSCs have high proliferation rates. Therefore, they 
could be attractive hosts to viruses like HCMV, which need proliferating cells to produce 
viral progeny. The hCMV-mediated decrease in neuronal differentiation may also support 
the above hypothesis as neurons do not proliferate, and may not function as productive 
hosts for the virus.  
mCMV models have been used to study the effect of viral infection on NSPCs in vivo.  
Much like hCMV, mCMV demonstrates a strong cellular tropism for NSPCs.  Thus, most 
mCMV models involve direct infection of NSPCs by the virus. mCMV infection of 
newborn mice leads to extensive infection of NSPCs and a loss of the NSPC pool and 
newly-born neurons51. The immune response against the virus begins with infiltration of 
macrophages and NK cells and the activation of CNS resident microglia57. CD8+ T cells, 
which are critical in controlling mCMV infection, follow the activation of innate immune 
cells71.  CD8+ T cells mediate clearance of CMV through cytolytic and non-cytolytic 
mechanisms, including IFN production55. HCMV-infected macrophages and microglia 
show enhanced activation enhance secretion of IL-6 and TNF. In addition, the immune 
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response may also affect NSPCs. Thus, the effects on NSPCs may be a result of a combined 
effect of the viral infection itself as well as the immune mediators released from different 
types of immune cells.  
 
 Zika Virus 
ZIKV has recently received considerable attention for its association with 
neurodevelopment deficits and tropism in NSPCs.  In embryonic brains, ZIKV can infect 
most neural cell types including NSPCs, intermediate progenitors, microglia and 
astrocytes72. However, it only has limited tropism in differentiated but immature neurons52. 
Much of the understanding of ZIKV’s effects on NSPCs has come from human NSPCs in 
vitro or non-human models72,73. Mouse models for research into various aspects of ZIKV 
infection suggested that ZIKV infected human NSPCs in vitro52,59. These studies suggested 
that ZIKV infect NSPCs and induced apoptosis.  An intraventricular injection of ZIKV into 
an embryonic mouse brain also revealed that ZIKV could cross the placenta, infect NSPCs 
and radial glial cells causing apoptotic cell death72. The mechanism of viral entry into the 
NSPCs is still under active research. The receptor tyrosine kinase AXL was the first 
receptor found to mediate ZIKV entry into NSPCs; however, other receptors are likely to 
be involved74.  
The role of the embryonic immune response to ZIKV infection is still poorly 
understood. Intrauterine inoculation of ZIKV in mice showed increased microglial 
activation, which correlated with decreased cortical thickness59.  Gene expression analysis 
in embryonic mice showed that there was an upregulation in genes associated with the anti-
viral immune response, demonstrating that the fetus is capable of activating at least some 
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of the classical anti-viral pathways72. Microglial cells in the fetal brain were also infected 
with the virus. This lead to  increased secretion of proinflammatory cytokines including 
IL-6, TNF, IL-1, and monocyte chemotactic protein-1 (MCP-1)from the microglia75. 
These cytokines have been shown to play a major role in modulating NSPC activity. 
Hyperplasia of ZIKV-infected Hoffbauer (macrophage) cells in the placenta, which may 
also contribute to the cytokine pool in the fetus was also reported 76. Another potential 
source of immune-mediated damage to the embryonic brain is the maternal immune 
system. qRT-PCR analyses of amniotic fluid of human subjects that had tested positive for 
ZIKV infections revealed elevated levels of proinflammatory cytokines including IFN, 
IL-6, IL4, IL-1, and TNF58. Transplacental infiltration of ZIKV and induction of 
apoptosis of NPSCs is responsible for many of the pathological outcomes in the embryos. 
However, the relative roles of maternal and embryonic immune response in ZIKV infection 
is still unclear.  
 
Measles Virus 
The passage of MV into the CNS is thought to be either through direct infection of the 
cerebral endothelial cells, or through infected leukocytes across the BBB. Much of the 
neurotropism has been understood by studying the biology of the receptors used by MV. 
CD46 and signaling lymphocyte-activation molecule (SLAM), also known as CD150, are 
the two known receptors used by MV for infection of cells in humans. CD46 receptor is 
widely expressed by most nucleated cells in the body. However, it is utilized predominately 
by the vaccine strains. On the other hand, CD150 is mostly expressed by T- and B-cells 
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and is utilized by both wildtype and vaccine strains of the virus.   Thus, how wildtype 
strains of MV are able to establish an infection in neural cells remains controversial.   
Transgenic mice expressing the human isoforms of the MV receptors are available.  
These mouse models include global or tissue-specific expression of the human receptors 
used by circulating MV strains (CD150/SLAM) or by vaccine strains (CD46)77,78.  Our 
laboratory uses a mouse model that expresses human CD46 under the control of the neuron-
specific enolase promoter (CD46+ mice), thereby restricting MV infection to mature CNS 
neurons78.  In the CD46+ model of MV infection, neonatal mice succumb to MV despite 
immune cell infiltration in the brain, whereas adults survive the infection with effective 
viral control60.  This provides an opportunity to examine how age-dependent differences in 
the immune response effect NSPC activity as well as how the anti-viral response impacts 
on brain development. Neonatal mice infected with MV demonstrated focal infection in 
the hippocampus, cortex, inferior colliculus, and paraventricular regions and in the 
Purkinje neurons of the cerebellum.  Both neonatal and adult CD46+ mice show CD4+ and 
CD8+ T-cell infiltration into the CNS. However, only adult mice successfully clear the 
infection. In fact, in adult mice that lack T- and B-cells did not clear the infection and both 
neonatal (90%) and adult (71%) showed signs of MV-related sickness. Therefore it is clear 
that T-cells are critical for MV control60.  Additionally, mice deficient in IFN also show 
greater MV-related illness and fail to control the virus in the brain.  IFN also exerted a 
direct antiviral effect on MV-infected primary neuronal cultures form CD46+ mice61.  It is 
hypothesized that IFNγ secreted from T-cells specifically is crucial for control of MV 
replication in neurons. Infection of CD46+ mice lacking the IFN type I and type II signal 
transducer, STAT1 (STAT1-KO mice), results in the survival of approximately 75% of 
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animals. Those mice that did not survive the infection died earlier than both T-cell deficient 
and IFNγ-KO mice. Moreover, the symptoms that they showed were different than the 
other genotypes, including “popcorn” seizures and earlier death within the first 6 dpi. Those 
mice that survived the initial 6-day period showed no signs of neurological damage. These 
mice also had normal T-cell infiltration and was not statistically different compared to wild 
type CD46+ mice79. Thus, CD46+ mice depend upon IFNγ production from T cells in order 
to control the virus and limit pathology, but IFNγ may utilize STAT1-independent 
pathways in order mediate its anti-viral effects in neurons.  
 In neonatal CD46+ mice, we explored how the anti-viral immune in the brain affected 
NSPCs, which are spared from MV infection in the CD46+. We observed that MV 
infection did not affect the pool of NSPCs, mature neurons, or astrocytes in wildtype 
pups62. However, a significant loss in the pool of differentiating but immature neurons 
(doublecortin+/CD24+) was observed. Moreover, there was significant increase in 
apoptotic cells in the neonatal CNS, although the lineage of the apoptotic cells remains to 
be identified. We also observed a decrease in neurogenesis (CD24+/BrdU+).  The pattern 
of decrease in immature neuronal pool did not match that of actively proliferating immature 
neurons in that the loss in the cell pool was observed much before the decrease in actively 
synthesizing cells.  These results indicate that the MV-induced immune response created 
bystander effects on immature neurons. We have observed extensive microglial activation 
in the neonatal CNS post-MV infection (Ganesan.P, unpublished data).  
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Borna Disease Virus  
BDV neuropathology has been studied predominately through experimental animal 
models of BDV because human samples have been challenging to confirm.  However, adult 
rats infected intracerebrally or intranasally with BDV usually develop an immune-
mediated biphasic behavioral disease. Rats display clinical signs and a histopathological 
that described for the naturally infected horse80. Experimental intra nasal infection of the 
rat has allowed the study of CNS spread of BDV. After initial replication in the neurons 
located at the site of entry (olfactory bulb) , BDV likely migrates intra-axonally in an 
anterograde or retrograde direction towards the CNS and ultimately disseminates into 
different regions of the brain81.  Within the CNS, BDV exhibit a preferential tropism for 
the limbic system, including the hippocampus which carries the highest viral load. Despite 
widespread persistent infection, BDV does not exert cytolysis in infected neuronal cells82.  
 The cell-mediated immune response to BDV plays an essential role in the 
development of neuropathology83. This was shown by studies on animals with antibiotic-
treated or immunocompromised animals. BDV infection of rats treated with 
cyclophosphamide, cyclosporin A, or of athymic rats did not lead to inflammation and 
development of disease84.  Both CD4+ and CD8+ T-cells infiltrated the CNS  during the 
immune-mediated pathology associated with BDV63. Adoptive transfer studies showed that 
cytotoxic CD8+ T-cells infiltrated the brain parenchyma and contributed to cortical atrophy 
through the release of perforin.  CD4+ T-cells were only found in perivascular areas in the 
CNS and did not contribute disease or neuropathology85. Cytokines and free radicals also 
contribute to BDV-mediated immunopathology. Levels of IL-6, TNF, and IL-1 mRNAs 
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are significantly increased in BDV-infected brains and their expression correlates with the 
severity of neurological signs86,87.  
BDV is considered as a noncytolytic virus. BDV-infected neuronal cells cultured 
in-vitro do not exhibit impaired growth or survival88. Nevertheless, BDV-infected 
organotypic slice cultures of the hippocampus from neonatal rats show a reduction in 
granular neurons. This loss is characterized by axonal retraction, decreased synaptic 
plasticity, and increased apoptosis.  In vivo analysis of BDV-mediated neuropathology is 
correlated with the inflammatory response accompanying the infection. Thus, it is difficult 
to attribute cell and tissue damage directly to BDV, but rather suggests that damage is due 
to the anti-viral immune response.  
Brnic et al and Scordel et al have shown that BDV can also infect human NSPCs 
in vitro64,89. Brnic et al reported that even though the NSPCs were infected, the NSPC 
proliferation and survival was not altered. When the NSPCs were allowed to differentiate 
into other neural cells, differentiation in the neuronal lineage was impaired by increased 
apoptosis of immature neurons. Scordel et al also observed a similar decrease in neuronal 
differentiation, specifically in GABAergic neurons. Evaluation of the expression of pro-
neuronal factors such as Noggin and ApoE showed a decrease in their expression. These 
results suggest that even though they are permissible to BDV, NSPCs are refractory BDV-
induced cell death. However, immature neurons become susceptible as they differentiate. 
These studies still do not address the role of immune cells on NSPC proliferation, survival, 
or differentiation, which seems to be a key factor in in vivo models. Ovanesov et al, 
observed that treating mixed neuron-microglia co-cultures with conditioned media from 
BDV-infected neurons (in the presence of astrocytes) caused microglial activation. 
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Microglial activation was characterized by changes in microglial morphology (rounded 
shape) with increase expression of major histocompatibility complex-I (MHC I), MHC-II, 
and IL-6 expression90. Therefore, we wanted understand if BDV-activated microglia also 
affect NSPC activity through a similar bystander effect.  
 
IV. NSPCs in other neurodegenerative and neuroinflammatory disease 
The role of NSPCs under in neurodegenerative diseases is an active area of study. In 
addition to normal NSPC functions such as CNS development, learning and memory, and 
maintenance of olfaction, NSPCs are altered in CNS diseases such as epilepsy, depression, 
and even natural aging91-93.  Whether such changes in NSPCs helps to delay or accelerate 
the neuropathology of disease is an open question. 
Conflicting evidence for changes in NSPC activity have been noted in age-related 
neurocognitive disorders such as Alzheimer’s disease (AD). In severely-affected 
Alzheimer’s brains, expression of neurogenic markers (doublecortin, NeuroD) is enhanced 
in the dentate gyrus and CA1 region of the hippocampus94. In mouse models of AD, 
accumulation of amyloid  (A) through transgene expression or intraventricular injection 
reduces NSPCs and newly-born neurons in the hippocampus95. A treatment of primary 
NSPCs in vitro also inhibits NSPC proliferation and production of new neurons.   These 
investigations show that NSPCs are responsive to the types of insults that occur in AD, 
although it is unclear how such changes in NSPC activity impact on disease progression in 
humans. Although the initiating factors that lead to AD pathology are not completely 
understood, inflammation plays a role in the progression of the disease96. Elevated levels 
of inflammatory cytokines such as IL-1,  IL-6, and tumor necrosis factor  (TNF) are 
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found in proximity to amyloid plaques and in the plasma and CSF of AD patients97-100. 
Studies have found that IL-1+ expressing microglia in the vicinity of A plaques are 
necessary for formation of neuritic plaques101. Moreover, transplanting NSPCs that over 
express IL-1 receptor antagonist (IL-1ra) rescued impairment in memory and neurogenesis 
in a mouse model of AD that had elevated levels of IL-1102. These studies indicate that 
immune activation affects NSPCs which may contribute to disease pathology.  
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the brain and 
spinal cord characterized by demyelination of axons and eventual neuronal death. 
Experimental autoimmune encephalitis (EAE) is a mouse model of MS currently widely 
used to model EAE in mice. Studies suggest that in EAE, there is induction of NSPC and 
oligodendrocyte progenitor cells (OPCs) proliferation in the SVZ. The subsequent 
migration of mitotically-active SVZ cells to the olfactory bulb and regions of demyelinated 
white matter is also enhanced103. Evidence from recent studies suggests that immune 
response in MS and experimental mouse models causes apoptosis of oligodendrocytes, 
which contributes to demyelination and ultimately neurodegeneration104,105. In the taiep 
model of MS, autosomal recessive genetic defects leads to an accumulation of microtubules 
in oligodendrocytes, which leads to decreased myelination on neurons.  The authors found 
transplanted OPCs could repopulate areas of demyelination but were unable to induce 
remyelination of axons. However, when coupled with acute inflammation, these OPCs 
were not only able to repopulate the demyelinated areas, they also successfully induced 
axonal remyelination106.  This indicates that in this model, inflammation played a 
supportive role and supported the reversal of pathology in the mice. 
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Studies from such disease states indicate that NSPCs are able to respond differentially 
in these neuropathologies. It is also important to note that the differential response is also 
influenced by the nature of the immune response. This suggests that the immune response 
plays an important role in modulating NSPCs and it is important to understand the role of 
cytokine/chemokine or trophic factors that may mediate these effects. 
 
 
 
 
 
 
 
 
 26 
 
Figure 1: Current hypotheses for IFN-mediated effect on NSPC activity. IFN binds to the IFN receptor 
(IFNGR1 and 2) and activates Janus-activated kinases 1 and 2 and Signal transducers and activators of 
transcription-1 (JAK-STAT1) pathway. In NSPCs, STAT1 activation blocks NSPC proliferation through 
decreased expression of cyclin/cyclin-dependent kinase (CDK) complexes. Studies with adult NSPCs 
report that IFN-mediated STAT1 activation results in increased neuronal differentiation.  STAT1 
activation leads to increased expression and secretion of the sonic hedgehog (Shh) protein, which in 
turn causes anomalous and concurrent expression of both glial and neuronal markers in the same 
cell107. Moreover, IFN-mediated STAT1 activation and Shh expression in granule precursor cells leads 
to increased NSPC proliferation.  In Paju cells, IFN-induced activation of the extracellular-signal 
regulated kinase-1/2 (ERK-1/2) increases neuronal differentiation, which may be independent of 
STAT1 activation108.  In C17.2 cells, IFN-mediated activation of c-jun N-terminal kinase (JNK) pathway 
caused neuronal differentiation, without the activation of ERK1/2 pathway109.  Developmental 
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cytokines such as Leukemia inhibitory factor and Ciliary neurotropic factor mediate glial differentiation 
through STAT3. IFN-mediated activation of STAT3 is observed in fetal NSPCs; however, the role of this 
pathway in NSPC differentiation is yet unclear.   
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V. IFN and its role in mediating NSPC activity  
Viral infections of the CNS lead to inflammation mediated by both resident microglia 
as well as infiltrating innate and adaptive immune cells. Viruses have diverse tropisms and 
capable of infecting multiple cell types in the CNS. The ensuing immune response helps in 
controlling the viral infection. However, as seen in the previous sections, anti-viral 
immunity may affect uninfected cells through cytokine release. Moreover, they can also 
express Major histompatibility complex (MHC) I and II molecules, which make them 
targets for immune cells110,111. IFN is a major anti-viral cytokine that is necessary for 
control of several viral infections in the CNS61,112-114. Both type I and II interferons play 
important roles mediating antiviral activities in the CNS. Type I interferons mediate 
immediate antiviral activities whereas immunomodulatory functions of IFN are crucial 
later in the viral infections in establishing an antiviral state115,116. IFN increases the 
expression of antiviral genes such as protein kinase R (PKR), the dsRNA-specific 
adenosine deaminase (ADAR), and guanylate-binding proteins (GBP1 and 2).  PKR 
inhibits viral dsRNA replication, whereas ADAR causes mistranslation of viral dsDNA117. 
GBP1 and 2 promote oxidative viral killing and helps in delivery of antimicrobial 
molecules to autophagolysozomes. In addition to these antiviral effects on infected cells, 
the bystander effects of IFN on NSPCs needs to be explored during viral infections. 
However, the outcomes and mechanisms through which IFN affects NSPCs are unclear.  
 
IFN: canonical and non-canonical signaling pathways 
To understand the effects of IFN, we need to acknowledge the diversity of 
signaling pathways that it initiates. IFN binds to the IFN receptor (IFNGR), which 
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consists of two IFNGR1 subunits and two IFNGR2 subunits.  Binding of IFN to IFNGR1 
causes heterotetramerization of the receptor, which then leads to activation of downstream 
kinases118,119.  IFN predominately activates the Janus associated kinase/Signal transducer 
and activator of transcription-1 (JAK/STAT) signaling pathway (Figure 1). Activation of 
JAKs results in the recruitment and activation (phosphorylation) of STATs at the receptor.  
Out of the seven STAT family members, STAT1 is the main downstream effector of IFNγ.  
Upon phosphorylation by JAKs, STAT1 homodimerizes and translocates to the nucleus, 
where it initiates the transcription of IFN-stimulated genes (ISGs).  There are 
approximately 500 ISGs that can be stimulated by IFN, including genes involved in viral 
clearance, cell cycle control, and inflammatory signaling118.  For example, IFN increases 
major histocompatibility complex (MHC) expression in a STAT1-dependent manner, 
leading to recognition of tumor cells by the immune system120.  IFN also inhibits 
proliferation of fibroblasts by reducing cyclin and cyclin-dependent kinase (CDK) 
expression, particularly that of cyclin D/CDK4121.  The profile of ISGs is dependent both 
on cell type and on other inflammatory signals that are received by the target cell (reviewed 
in 122).  Thus, the phenotypic response to IFN also varies depending upon cell type, which 
is reflected in conflicting reports of neuroprotection and toxicity with IFN treatment123-
125.   
To evade clearance from the body, many viruses inhibit STAT1 function and 
expression, thereby abrogating the anti-viral response of the cell126,127.  However, IFN also 
signals through STAT1-independent mechanisms, which may be activated alone or in 
parallel with STAT1-dependent pathways128.  These pathways result in protective as well 
as pathological outcomes. Primary hippocampal neurons utilize STAT1-independent 
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pathways for viral control, possibly because endogenous STAT1 expression is inherently 
low in these cells79.  Neurons also activate extracellular regulated kinase-1/2 (ERK-1/2) 
signaling in response to IFN, which confers neuroprotection against apoptotic insults.  In 
contrast, primary astrocytes activate STAT3 upon IFN treatment, which leads to the 
production of neurotoxic factors129.  IFN stimulation may also lead to recruitment of 
adaptor molecules such as the c-Cbl proto-oncogene and the GTPases Ras and Rap1130.  
Like STAT1-dependent signals, activation of Rap1 signaling inhibits cell proliferation in 
human embryonic kidney cells131. Therefore, IFN may activate multiple pathways that 
limit cell growth, which could be advantageous for controlling viral replication in a rapidly 
dividing cell. In lung epithelial cells, where STAT1 is activated through the activation of 
the Phospholipase C-gamma2/Protein Kinase C/Src (PLCγ2-PKCα-src) pathway in a JAK-
dependent manner. This pathway causes increased expression of Intercellular Adhesion 
Molecule (ICAM)-1132 and facilitates binding and transmigration of immune cells into 
tissues. Therefore, in addition to pathways that are STAT1-independent, other signaling 
proteins and adaptor proteins may link JAK and STAT1 indirectly in certain cell types.  
 
IFN-mediated signaling in NSPCs 
The diversity of IFN-mediated signaling pathways raises the question of how IFNγ 
may affect NSPCs.  The role of IFN is particularly important because the JAK-STAT 
family of proteins has been implicated in NSPC proliferation and differentiation133-135. 
Several reports show that IFN inhibits proliferation of murine NSPCs derived from the 
adult SVZ in vitro136-140.  Moreover, NSPCs derived from mice lacking IFN show 
enhanced neurogenesis and proliferation141. There is evidence that IFN can alter NSPC 
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function through activation of the STAT family of proteins.  Lum, et al showed that when 
adult SVZ-derived NSPCs were treated with IFN, there was activation of both STAT1 
and STAT3137. Conversely, Pereira et al observed that IFN-treated NSPCs derived from 
postnatal brains (P7-P9) showed increased STAT1 activation but no change in STAT3 
activation138. One reason for this discrepancy could be the time point at which STAT3 
activation was measured; the former study assessed STAT3 activation four days post-
treatment whereas the latter measured activation at 15 minutes post-treatment. Studies in 
many cell types indicate that STAT1 and STAT3 play opposing roles in cell proliferation; 
STAT1 is generally anti-proliferative and STAT3 is pro-proliferative142.  This explains the 
role of STAT1 in mediating anti-proliferative effects of IFN on NSPCs, but the role of 
STAT3 is yet unclear.   Previous studies in mouse embryonic fibroblasts have also shown 
that both STAT1 and STAT3 may be activated in a cell at the same time. However, STAT3 
activation rapidly declines due the activity of inhibitors such as suppressor of cytokine 
signaling-3 (SOCS3)143. 
The sonic hedgehog (Shh) protein also plays an important role in NSPC 
proliferation and fate specification144.  In NSPCs, IFN induces Shh expression.  These 
studies show that IFN-mediated Shh expression and signaling results in increased 
proliferation of cerebellar neural precursor cells145. Other studies demonstrate that 
induction of Shh by IFN results in a dysregulated cell-fate characterized by expression of 
glial and neuronal markers in the same cell107.  IFNγ also increases Shh expression in 
adipocyte precursors, suggesting that IFNγ may act broadly on undifferentiated cells to 
induce differentiation or growth146.  
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One outstanding question is how NSPC differentiation is affected by IFN during 
pathological insults. In vitro studies on adult murine NSPCs indicate that IFN induces 
neuronal differentiation136,137,139.  Pereira et al showed that infusion of IFN into the mouse 
SVZ decreased neuronal differentiation in a STAT1-dependent manner138. However, Ben-
Hur et al did not observe any changes in differentiation in IFN-treated NSPCs derived 
from neonatal rat striatum140.  In contrast to many studies on adult NSPCs, embryonic 
NSPCs exhibit decreased neuronal differentiation in response to IFNγ147. Together, these 
studies suggest that NSPCs may differ in their responsiveness to IFN depending upon 
anatomical location and the age of the host.    
A number of other cytokines, including Leukemia inhibitory factor (LIF) and 
Ciliary neurotropic factor (CNTF), activate JAK-STAT signaling and regulate NSPC cell 
fate.  During CNS development, these cytokines trigger glial differentiation in NSPCs 
through activation of STAT1 and STAT3. However, they cause glial differentiation only 
during late gestational periods (embryonic day 16 and later).  STAT-dependent gliogenic 
activity is repressed during the neurogenic period (embryonic days 10-14) through 
epigenetic inhibition of glial gene expression135,148. Whether IFN synergistically affects 
LIF and CNTF signaling during development is unknown.  However, one could conjecture 
that IFN may augment glial differentiation at later stages in development through 
activation of JAK-STAT signaling.   
In addition to STAT1, mitogen-activated protein kinases (MAPK) have also been 
implicated in mediating neuronal differentiation in cell lines. IFN induces neuronal 
differentiation through the ERK-1/2 pathway in the human neuroblastoma Paju cell line108. 
In a murine cerebellar cell line, IFN causes neuronal differentiation through the activation 
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of c-jun N-terminal kinase (JNK) pathway.109  Moreover, inhibition of the JNK pathway 
but not the ERK-1/2 pathway reversed the effects of IFNγ.  Other MAPKs, such as the p38, 
have also been implicated in mediating neuronal differentiation149.  Admittedly, these 
studies were conducted in transformed cell lines and not in primary NSPCs108.  However, 
they highlight the importance of MAPK signaling as an alternative pathway for influencing 
cell fate decisions downstream of IFN. A summary of these pathways is depicted in 
Figure 1.  
The fact that IFN affects NSPC proliferation and cell fate specification is well 
established, although the necessary signaling pathways are still being defined.  Variables 
such as the age of the host, brain region, and species may impact on the NSPC response to 
IFN. Regardless of the differences in model systems, STATs play a major role in 
mediating the effects of IFN on NSPC activity. Activation of non-canonical pathways, 
such as MAPKs, and crosstalk with other STAT signaling pathways may also be involved.   
It will be important to account for the mutable responses of NSPCs to IFN when 
considering how these cells react in in vivo disease models.  Moreover, the mechanisms 
that act downstream of these signaling pathways such as IFN-mediated cell cycle control 
and survival pathways are still undefined. This dissertation will also attempt to define these 
pathways which will further the understand of IFN-mediated control NSPC activity. 
 
Role of IFN in viral infections and effects on NSPCs  
In addition to viral infection, NSPC activity may be affected through a bystander effect 
from anti-viral cytokines150,151. IFN is critical in controlling the spread of many 
neurotropic viruses including measles virus, Theiler's virus, herpes simplex virus and 
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Sindbis virus61,152-154.  Even though the anti-viral and immunomodulatory roles of IFN are 
well documented, its role in affecting NSPC activity in the context of viral infections is 
less clear.  Recent research indicates that IFN may affect NSPC survival, proliferation, 
and neurogenic potential during infections, depending on the model system and on the 
cellular tropism of the virus.  Here, we examine the specific role of IFN on NSPCs in 
different models of neurotropic viral infections.  
Studies using intranasal delivery of HSV NSPCs are not infected by HSV-1, suggesting 
that changes in NSPC function are due to the inflammatory environment 68. During the 
chronic phase of HSV-1 infection, activated CD8+ T cells are the major source of IFN in 
the CNS.  Co-culture of virus-activated CD8+ T cells and NSPCs showed reduced NSPC 
proliferation and differentiation into glial cells53. When antibodies blocking IFN binding 
to its receptor were used, the decrease in proliferation was abrogated. Together, these 
findings demonstrate that IFN may be a key factor in dictating how NSPCs respond to 
cytotoxic T cells.  These studies further suggest that the IFN-mediated effects on NSPCs 
may affect functional recovery post-HSV-1 infection. 
In a murine model of mCMV infection, IFN increases the expression of MHC class I 
and II on NSPCs, which would allow recognition by infiltrating T cells155.  mCMV; 
however, is able to counteract the IFN-mediated induction of MHC class I in NSPCs156.  
These mechanisms may allow the virus to evade immune clearance and establish latency 
in the NSPCs. Moreover, MHC expression is important for neuronal development and 
synaptic refinement157.  Therefore, a CMV-mediated decrease in MHC expression could 
hamper the development of neuronal networks, particularly during the formative stages of 
brain development.   
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Our laboratory uses the CD46 mouse  model, where MV infection is restricted to 
mature CNS neurons78.  In CD46+ adult mice, IFN is required for non-cytolytic clearance 
of MV from infected neurons61.  In neonatal CD46+ mice, we explored how the anti-viral 
immune in the brain affected NSPCs, which were spared from MV infection.  IFN 
preserved the NSPC pool during MV infection, but could not prevent a decline in 
neurogenesis.  Moreover, newly-differentiated neurons (doublecortin+) were lost 
regardless of IFN expression62. These data indicate that IFN may be critical in protecting 
uninfected NSPCs during an anti-viral immune response, but cannot protect new neurons 
from the effects of neuroinflammation.  
A central role for inflammation has been acknowledged in many CNS diseases158-160.  
However, the role of inflammation, and specifically of IFN, in modulating NSPC 
functions is under active study.  IFN is one variable that affects how NSPCs respond in 
inflammatory environments.   Because IFN is a pleiotropic cytokine, alterations in IFN 
expression often affect multiple neural and immune cells, which can further impact on 
NSPC function.  Taking into account the diversity of signaling pathways activated by IFN, 
and variability of its effects on NSPCs in different systems, IFN may exert subtle 
alterations in pathological outcomes in neuroinflammatory conditions. The discovery of 
multipotent NSPCs in the adult brain has also generated interest in how these NSPCs are 
affected by inflammation in the mature brain, particularly during neurodegenerative 
disease. 
Some outstanding questions remain. How does IFN mediate its effects in NSPCs 
Which immune cells mediate the bystander effect? What role do microglia, which are the 
resident immune cells in the CNS and can be protective in some inflammatory 
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environments, play in this model? Which immune mediators are released by infiltrating 
and resident immune cells?  In this thesis, we will address the effect of immune mediators, 
such as IFN,  on NSPCs. Microglial activation and their role in CNS pathology during 
viral infections have been studied in other models. However, how the result of microglial 
interactions with infected neural cells and the subsequent effects on NSPCs are not known. 
To study these interactions, we have developed neuron-microglia co-culture model to 
explore the effects of virus-induced microglial activation on NSPC proliferation and 
differentiation. 
Therefore, this study aims to define mechanisms through which the immune response 
influences NSPCs and the implications of these effects on pathology and brain 
development during neurotropic viral infections. 
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Chapter 2: Materials and Methods 
I. Cell culture  
Neural stem/progenitor cells (NSPCs) 
Animal use protocols were reviewed and approved by the Duquesne University 
Institutional Animal Care and Use Committee. CD46+/WT (wildtype) and 
CD46+/STAT1-knockout (STAT1-KO) mice were a generous gift from Dr. Glenn Rall 
(Fox Chase Cancer Center)161. The genotype of the STAT1-KO mice used in these 
experiments was confirmed by PCR analysis of tail biopsy DNA79. NSPC cultures were 
prepared from wildtype CD46+/WT or STAT1-KO mouse embryos on embryonic day 12.5 
(E12.5) as described previously with modifications162.  Briefly, cortical tissue was digested 
using trypsin-EDTA solution (0.05%, Mediatech, Inc., Manassas, VA) to obtain a cell 
suspension.  The trypsin was neutralized using an equal volume of soybean trypsin 
inhibitor (1mg/mL, Sigma-Aldrich, St. Louis, MO), and the cell suspension was passed 
through a 70μm cell strainer (Thermo Fisher Scientific, Waltham, MA).  Cells were 
centrifuged (1150 rpm for 5 min) and the cell pellet was resuspended in 1 mL NSPC culture 
medium consisting of DMEM (Mediatech, Inc., Manassas, VA), 1X B27 supplement 
without vitamin A (Thermo Fisher Scientific, Waltham, MA), 1X N2 supplement (Thermo 
Fisher Scientific, Waltham, MA), heparin (2μg/mL, Sigma-Aldrich, St. Louis, MO), 
murine epidermal growth factor (20ng/mL, Peprotech, Rocky Hill, NJ) and murine 
fibroblast growth factor-2 (20ng/mL, Peprotech, Rocky Hill, NJ).  The NSPCs were 
cultured in suspension at 2*106 cells in 5 mL NSPC culture medium and maintained at 
37°C/5% CO2 in a T-25 flask (Thermo Scientific-Nunc, Waltham, MA Cat# 12-565-49).  
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After 3 days in vitro (DIV), neurospheres were disassociated with 0.25% trypsin-EDTA 
(Thermo Scientific, Cat# 25200056) , counted, and used for subsequent experiments. 
 
Microglia-Neuron co-culture system 
To study the effects of immune activation following measles virus neuronal infection on 
NSPC activity, primary microglia were cultured first with primary neurons in a co-culture 
system. Conditioned medium form the co-culture was used to treat NSPCs cultured in vitro 
as a monolayer.  
 
Primary Embryonic neuronal culture 
Primary neurons were cultured from E. 15.5 mice as previously described. Briefly, 
Cortexes form E15.5 were treated with pre-warmed with 0.05% Trypsin-EDTA for 15 mins 
at 37°C. The tissue was washed 3 times with 5 mL DMEM supplemented with 10% FBS 
(FBS; 10%, Atlanta Biologics, Lawrenceville, GA, Cat# K11050), 1% L-glutamine (200 
mM, Cellgro, Manassas, VA, Cat# 25-005-Cl) and 5% Penicillin-Streptomycin (Cellgro, 
Manassas, VA, Cat#30-002-Cl). Trypsin-EDTA was inactivated with FBS. The tissue was 
dissociated with a flame polished pipets and passed through a 70μm cell strainer to remove 
debris. The suspension was transferred to a 15mL tube and underlaid with 2mL FBS and 
centrifuged at 1300 rpm for 5 mins at 21°C. The supernatant was removed and the pellet 
was resuspended in neurobasal medium (NBM; Thermo Fisher Scientific, Waltham, MA, 
Cat# 21103) supplemented with 1X B27 (Thermo Fisher Scientific, Waltham, MA; Cat# 
17504-44), 1% L-glutamine, and 25 μM glutamic acid. The cells were grown in Poly-D- 
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lysine-coated 24-well or six-well plates (Corning Costar, Corning Incorporated, Corning, 
NY) for four days at 37°C. 
 
Primary microglia culture 
Stage 1: Mixed microglia-astrocyte culture 
The base of a 75 cm2 culture flask was coated with 10ml poly-D-lysine 
hydrobromide (100 μg/ml, MP Biomedicals, Solon, OH; Cat# 0215017525) and allowed 
to set overnight at 20°C prior to dissection.  Three to four pups (1-3 days old) were culled 
by cutting both carotid arteries (without decapitating the mouse; otherwise subsequent 
handling is made difficult). The skin over the skull was cleared under aseptic technique. 
This was achieved by making a crucifix incision over the cranium (transverse incision at 
the base of the skull and the vertical incision along the midline of the skull up to the anterior 
part of the skull). New straight forceps were then used to peel away the skin on the scalp 
to fully expose the skull. A pair of corneal scissors were used to cut along the suture lines. 
A 3rd pair of straight forceps were then used to ‘peel’ the skull away and to fully expose 
the brain. New curved forceps were then inserted under the base of the brain and the brain 
was gently lifted away from the skull base. The brain tissue was minced using a #10 scalpel 
and the cleaned brain is then placed in a new culture dish with 2 ml of tissue digestion 
enzyme (Papain 20 U/mL activated with 5mM L-cysteine). The brain/enzyme suspension 
were transferred gently into a 15 mL centrifuge tube using a 5 ml serological pipette. The 
tube was maintained in the incubator at 37 °C for 20 min to allow for enzymatic 
disaggregation. After the allocated time, DMEM with 10% fetal bovine serum (FBS)/1% 
Penicillin/streptomycin (P/S) is added to the suspension (1:1 ratio) to neutralize the 
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enzyme. The single cell suspension was gently agitated by moving the solution up and 
down 20 times using a 1 ml plastic transfer pipette with care being taken to avoid bubble 
formation. This suspension was passed through a 70 μm nylon cell strainer into another 50 
mL tube. The suspension is then centrifuged in a cooled (4 °C) centrifuge at 1000 x g for 
5 min. The cells were resuspended in 6 mL of 30% Percoll solution (GE Healthcare Bio-
Sciences, Pittsburgh, PA; Cat#17-0891-01) and centrifuged at 500 x g for 20 min at 4C.  
The cell pellet was washed by resuspending with 6mL DMEM and centrifuged again at 
1000 x g for 10 min at 4C. The cells were suspended in 1 mL DMEM and counted. The 
poly-D-lysine was removed and the flasks were washed once with PBS. All of the cells 
from the three brains was added to the flask in 20 mL of DMEM incubated at 37 °C. After 
2 days, the DMEM is replaced with a fresh DMEM. When the cells are approximately 80-
90% confluent, they are used for purification (Stage 2). 
Stage 2: Purification of murine microglia cells from the mixed glia cell culture 
At this stage, the culture is a mixture of microglia and astrocytes.  Once the flask 
reaches a 90% confluence level (after 10-14 days), the microglial cells are detached from 
the flask using the heated orbital shaker machine at 240 rpm for 1.5 - 2 h (37°C). The 
suspension was transferred into a 50 mL centrifuge tube and then centrifuged at 190 x g 
for 8 min at 21C. The supernatant was discarded and the cell pellet is resuspended in one 
mL DMEM. The microglia are counted by trypan blue exclusion and prepared for neuronal 
co-culture.  
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MV infection of primary neurons 
To prepare stocks of measles virus (MV), Vero cells were maintained in Dulbecco’s 
modified Eagle media (DMEM) supplemented with 10% FBS, 2 mM L-glutamine, 100 U 
of penicillin per ml, and 100 ng of streptomycin per ml. MV-Edmonston (MV) was 
purchased from American Type Culture Collection (Manassas, Va). The virus was 
passaged in Vero cells (three passages), titered in Vero cells via plaque assay, and stored 
at -80C until further use.    
On the fourth day post-plating of neurons, 75% (1.5 mL/well from 24-well plate or 
3 mL/well from 6-well plates) of NBM was removed from each medium and saved in a 
centrifuge tube. The neurons were infected with Measles virus (MV) by incubating with 1 
MOI (200 L/well for 24- well plates and 500 uL/well for 6-well plate) of MV at 37°C for 
one hour. Meanwhile, the volume of saved NBM was made up to 100% by adding fresh 
NBM (without glutamic acid). The virus was removed, cells washed with 1X PBS (without 
Ca2+/Mg2+), and the saved NBM was added back to the wells. The cells were incubated at 
37°C for four days.  
 
Primary neuron and microglia co-culture  
Four days post-infection of primary neurons, microglia were processed as described 
(stage 2). After resuspension in DMEM, the microglia were counted and appropriate 
number of cells were added to neuronal culture (100,000 cells/well for 6-well plates and 
25,000 cells/well for 24-well plates).  Four days post-co-culturing, the medium was saved 
(for ELISA) or added to NSPCs monolayer in the differentiation phase. The co-cultured 
cells in 24-well plates were fixed by treating with 4% paraformaldehyde (PFA) in PBS for 
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20 minutes, permeabilized with Triton X-100 (0.2% in PBS) for 15 minutes, washed with 
1X PBS (without Ca2+/Mg2+), and stored in sterile PBS (without Ca2+/Mg2+) at 4°C until 
further use. Cells in the six-well plate were used for RNA extraction to be used in qRT-
PCR and processed as described below.  
 
NSPC monolayer culture 
Twenty-four well plates with 12mm coverslips or six-well plates were coated with 
poly-D-lysine (100 μg/mL) and Laminin (1μg/mL).  NSPCs (Passage 1; 20,000 cells/well 
for 24 well plate and 200,000 cells for 6-well plate) were grown in NSPC growth medium 
in the plates and allowed to attached for one day. The medium was changed with 
differentiation medium (growth medium w/o growth factors) or neuron-microglia 
conditioned medium and allowed to differentiate for 4 days. The cells were fixed with 4% 
PFA for and permeabilized using 0.2% Triton X-100 for 15 minutes at 20°C, washed with 
1X PBS (without Ca2+/Mg2+), and stored at 4°C until further use.  NSPCs in the six-well 
plates were used for BrdU assay or flow cytometry to measure NSPC differentiation.  
 
II. Neurosphere assay 
NSPCs (passage 1) were cultured in T-25 flasks at 20,000 cells/mL with different 
concentrations of interferon-gamma (IFN; 1-1000 U/ml).  IFN solutions were prepared 
by making 10X solutions in NSPC culture medium from a 1000 U/μL stock solution (BD 
Biosciences, San Jose, CA).  As a negative control, heat-inactivated IFN (H-IFN) was 
prepared by boiling IFN (1000U/mL) at 100°C for 5 min.  After IFN treatment, the 
neurospheres were imaged after 3, 5, or 7 DIV using an EVOS FL microscope (Thermo 
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Fisher Scientific; Waltham, MA).  Five fields were taken from each flask at 2X 
magnification by an observer blinded to experimental conditions.  The neurosphere 
diameter (μm) and area (pixel2) was measured for each neurosphere using Image J software 
(Version 1.6.0_65).  The average diameter for each treatment group was calculated and 
graphed as percent of the untreated group.  Neurosphere area was graphed as a histogram 
plot using pixel2/neurosphere for each treatment condition.  
 
III. Bromodeoxyuridine (BrdU) Assay 
Single-pulse BrdU assay in neurospheres 
WT and STAT1-KO NSPCs (100,000 cells/mL) were cultured in T-25 flasks and 
treated with IFN (1-1000 U/ml) for 3 DIV.  BrdU staining was performed following 
manufacturer’s instructions using the BD Pharmingen™-FITC BrdU Flow Kit (BD 
Biosciences, San Jose, CA).  On DIV 3, the neurospheres were treated with BrdU (25μM) 
solution for 90 min. at 37°C.  The neurospheres were dissociated using 0.05% trypsin 
solution (3 min at 37°C) into a cell suspension.  BrdU content was determined by 
incubating the cells with a FITC-conjugated anti-BrdU antibody (1:50; 559619, BD 
Biosciences, San Jose, CA) for 30 min.  A FITC-conjugated isotype control antibody (1:50; 
556649, BD Biosciences, San Jose, CA) was used as a negative control for BrdU staining. 
The cells were counterstained with 7-Aminoactinomycin D (25μM) for 15 min at 20°C. 
Single cells (100,000 events per sample) were analyzed by flow cytometry (Accuri C6, BD 
Biosciences, San Jose, CA) using an initial gate to exclude debris.  Signals for BrdU-FITC 
(FL1) and 7-AAD (FL3) were compensated by subtracting FL3 from FL1 (2%) and FL1 
from FL3 (10%) as per manufacturer’s guidelines prior to analyses.  Co-labeling with BrdU 
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and 7-AAD staining allowed for discrimination of cell cycle phases: G0/G1 (7-AAD low, 
BrdU low), S-phase (BrdU high, 7-AAD intermediate), and G2/M-phase (BrdU low, 7-
AAD high).  
 
 BrdU pulse-chase assay 
For the BrdU pulse-chase assay, NSPCs were grown in T-25 flasks with or without 
IFN (100 or 1000 U/mL) treatment as described for the BrdU assay. On DIV 3, the 
neurospheres were pulsed with BrdU for one hour and washed with 1X PBS and stored in 
1X PBS until further use. Neurospheres were harvested at 0, 3, 6 and 9 hours post-BrdU 
washout.  Neurospheres for the zero-hour time point were harvested immediately post-
BrdU washout. For the other time points, the neurospheres were resuspended in NSPC 
culture medium and harvested at the respective time points. Following harvest, the protocol 
for the BrdU assay described above was followed for flow cytometric analysis.   
 
Single-pulse BrdU assay in cell monolayers 
WT-CD46+ NSPCs (20,000 cells/well) or astrocytes (250,000 cells/well) grown in 
6-well plates from conditioned medium treatments were pulsed with BrdU (25μM) and 
incubated at 37°C for 90 mins. Post-BrdU treatment, the medium was discarded and the 
cells were detached using with 1mL/well pre-warmed 0.05% Trypsin-EDTA. The trypsin 
was neutralized using an equal volume of soybean trypsin inhibitor. The detached cells 
were collected in 1.5 mL microcentrifuge tubes and centrifuged at 300g for 5 mins at 21°C. 
Mixed glial cultures were incubated with IFN for 24 or 72 h, and BrdU (25 mM) was 
added for 1 h prior to harvest. Cells were trypsinized, fixed and permeabilized using 19 
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cytofix/cytoperm solution (BD biosciences). BrdU assay was performed as described in 
single pulse BrdU assay protocol. 
 
IV. Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) Assay 
The TUNEL assay was performed using the Trivigen Flow TACS Apoptosis kit 
(R&D Systems, Minneapolis, MN) according to manufacturer’s protocol. Briefly, 50,000 
cells/mL of NSPCs (WT or STAT1-KO) were cultured with or without IFN (100 and 1000 
U/ml) for 3 DIV.  Neurospheres were collected by centrifuging at 400 rpm and trypsinized 
as described above.  The cells were fixed in 3.7% PFA for 10 min, permeabilized using 
100 μL cytonin solution (Trevigen, Gaithersburg, MD, #4876-60-01) for 30 min, and 
treated with 25μL/sample TdT labeling mixture for 1 hr at 37°C. The cells were then treated 
with 25μL/sample of strep-fluorescein for 10 min in the dark and washed 1x in PBS.  
Neurosphere cells (1x10^5 cells/sample) were analyzed by flow cytometry to quantify 
TUNEL positive cells (FL1 channel) with gating to exclude cellular debris.  DNase-treated 
and TdT enzyme-omitted groups were used as positive and negative controls for the assay, 
respectively. 
 
V. Carboxyfluorescein succinimidyl ester (CFSE) assay 
CellTrace CFSE Cell Proliferation Kit (Invitrogen, Grand Island, NY) was used to 
perform CFSE labeling. A single cell suspension of WT or STAT1-KO NSPCs (100,000 
cells/mL) were labeled with 5μM CFSE in pre-warmed PBS at 37°C for 10 mins. The cells 
were washed with cold NSPC culture medium, centrifuged at 1500 rpm, and resuspended 
in fresh NSPC culture medium. The NSPCs were added to T-25 flasks, treated with 100 
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U/mL IFN NSPC culture medium, incubated at 37°C/5% CO2.  After 2, 3, or 5 DIV, the 
neurospheres were dissociated using 0.05% trypsin (3 min at 37°C) and fixed using 3.7% 
paraformaldehyde (PFA) in PBS (5 min at 20°C).  The fixed cell suspension was analyzed 
by flow cytometry to measure the intensity of the CFSE signal (FL1 channel) per cell 
(22,500 cells per condition in each experiment; n=3). 
 
VI. Immunofluorescence assay 
NSPCs were grown as neurospheres and passaged as indicated above for plating onto 
coverslips. The cells were grown in 24-well plates on poly-d-lysine/laminin-coated 
coverslips (10,000 cells/well) in NSPC culture medium (with EGF and FGF). On DIV2, 
NSPC culture medium was replaced with differentiation medium (47.4 mL DMEM, 1mL 
B27 without Vit A, 0.5 mL N2, 100 uL heparin; 1.8 mL/well). The cells were treated with 
100 U/mL IFNγ. Two hundred uL of 10X solution of IFNγ (1000U/ml) was added to each 
well.  
On 2 and 6 days-post IFNγ treatment, cells were washed with PBS and fixed in a 
solution of 4% PFA for 20 minutes at room temperature. The cells were permeabilized with 
0.2% Triton X-100 solution. The NSPCs were stained for nestin, MAP2 and GFAP using 
primary antibodies at the same concentration indicated in Table 3. The nuclei were stained 
using Hoechst nuclear stain (1:10,000). The coverslips were mounted on glass slides with 
5 L of prolong gold mounting medium (Thermo-Fisher Scientific, Waltham, MA). The 
mounting medium was allowed to dry and the cells were imaged using the EVOS FL 
microscope (Thermo Fisher Scientific; Waltham, MA).  
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VII. Western blot 
NSPCs were cultured in T-75 flasks by seeding 50,000 cells/mL in NSPC culture 
medium.  The cells were treated with IFN (100 U/mL) or left untreated. On DIV 2, 3, or 
5, the neurospheres were collected by centrifugation at 400 rpm and lysed using 200μL 1x 
Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA) with protease inhibitor 
cocktail (10 uL/106 cells; Sigma-Aldrich, St. Louis, MO).  The lysate was centrifuged at 
11,000 rpm and the supernatant was stored at -80°C until analysis.  The protein 
concentration of each lysate was measured using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific, Waltham, MA).  For each sample, 20μg of lysate was subjected 
to sodium dodecyl sulfate–polyacrylamide gel electrophoresis on NuPAGE 7% Tris-
acetate gels (Thermo Fisher Scientific, Waltham, MA).  The gel was blotted onto 
Immobilon-FL Membrane (Millipore, Billerica, MA) and the membranes were blocked 
using a 1:1 mixture of 1X phosphate buffered saline/Tween-20 solution (Sigma-Aldrich, 
St. Louis, MO) and Odyssey blocking buffer (Licor Biosciences, Lincoln, NE) for 60 min 
at 20°C.  The membranes were treated with primary antibody solutions diluted in Odyssey 
blocking buffer overnight at 4°C on a rocker.  The membranes were washed thrice with 
PBS-Tween for 10 min each and incubated in secondary antibody solutions (goat anti-
rabbit 680 or donkey anti-mouse 800 (1:10000); Licor Biosciences, Lincoln, NE) for 60 
min at 20°C.  The membranes were washed thrice in PBS-Tween and imaged on the 
Odyssey Infrared Imaging System (Licor Biosciences, Lincoln, NE).  Individual bands 
were quantified using Image Studio software (Licor Biosciences, Lincoln, NE, version 
4.0.21). The signal from each band(s) was normalized against the GAPDH signal as a 
loading control.  Primary antibodies used were as follows: anti-phospho STAT1 (Y701, 
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#612133), anti-STAT1 (N-terminus, #610120), anti-STAT3 (610190) from BD 
Biosciences; anti-phospho STAT1 (S727, #9177) anti-Cyclin D1 (#2978), anti-Cyclin D3 
(#2936); pRb S780 (#8180), pRb S807/811 (#8516), pRb S780 (#9307), Rb-total (#9313) 
anti-phospho STAT3 (#9131) form Cell Signaling Technology; pRb S795 (1:500, 
ab47474) from Abcam; and anti-cdk4 (MAB8879), anti-cdk2 (#07-631) anti-cyclin E 
(#07-687) from Millipore.  All primary antibody concentrations were 1:1000 unless 
otherwise stated. 
Blots for STAT1 and STAT3 displayed two bands, owing to the presence of two 
isoforms of each of these proteins. For the STAT proteins, both bands were quantified 
together.  Blots for cyclin D1 also showed two bands, which correspond to phosphorylated 
(upper band) and unphosphorylated (lower band) forms. These bands were quantified 
together (for total cyclin D1 levels) and individually (for levels of phosphorylated and 
unphosphorylated cyclin D1, respectively).  All values of STAT proteins and cyclin D1 
were normalized to GAPDH for analysis.   
 
VIII. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
RNA extraction 
Cells from co-cultured 6-well plates were detached with 1mL/well pre-warmed 
0.05% Trypsin-EDTA. The trypsin was neutralized using an equal volume of soybean 
trypsin inhibitor. The detached cells were collected in 1.5 mL microcentrifuge tubes and 
centrifuged at 300g for 5 mins at 21°C. The supernatant was discarded. RNA extraction 
was performed using Qiagen RNeasy kit (Qiagen; Hilden, Germany; Cat# ID: 74104) as 
per the manufacturer’s protocol. RNA was quantified using NanoDrop (ThermoFisher 
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Scientific, Waltham, MA). The RNA concentration for each sample was recorded and 
stored at -20°C until further use. The volume needed for 1g RNA was calculated.  
 
Reverse transcription 
Reverse transcription was performed using the Quantitect Reverse transcription kit 
(Qiagen, Cat# 205311). Stored RNA was thawed immediately before use and kept on ice. 
Sample RNA (1g) was pipetted in an RNase free microcentrifuge tube.  Genomic DNA 
elimination reaction and reverse transcription was performed as per the kit directions. This 
reaction yielded 20L of cDNA (50ng/L) which would be used for qRT-PCR 
experiments. 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
The reverse transcription product (50 ng/L, 20L) was diluted to 6.25 ng/L by 
adding 160L of RNase free water.  The master mix was prepared by diluting the forward 
and reverse primers for each gene with Eve green dye (Midsci, Valley Park, MO; Cat# 
BEQPCR-R). The master mix (37 L/tube) was added to a microcentrifuge tube and the 
diluted cDNA (24L/tube) was added to it. Seventeen L of the prepared solution for each 
sample was added to a 96-well plate in triplicate. RNA was quantified by detection using 
the StepOnePlus Real-Time PCR System (ThermoFisher Scientific). CT values were 
calculated for each sample. The fold change value for all the sample were calculated in 
comparison to uninfected+ no microglia group. The fold change values were graphed. 
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IX. NSPC characterization  
To ascertain that the cultured E12.5 NSPCs were at the desired developmental stage, 
the cultures were characterized for co-expression of the developmental markers, nestin, 
SOX2, and PAX6 (Table 4) using immunocytochemistry (ICC).  Cellular composition of 
neurosphere cultures was determined by staining for neural markers (Table 3) and 
quantifying their cellular expression using flow cytometry. Levels of marker expression 
(Table 5) and their temporal changes in an in vitro culture were determined using in-cell 
western assay (ICW). These assays and techniques are described below in detail. For all 
the characterization methods, NSPCs were grown as neurospheres first, On DIV3, these 
neurospheres were passaged and cultured as monolayers in tissue culture plates.  
 
Immunocytochemistry (ICC) 
NSPCs were grown in Poly-D-lysine/laminin coated coverslips in 24-well plates at 
20,000 cells/well. The cells were cultured in NSPC culture medium Coverslips were 
blocked for one hour at 20°C using blocking solution (4% goat serum in 1X PBS without 
Ca2+/Mg2+). All primary and secondary antibody solutions were prepared by diluting in 
blocking solution. Coverslips were incubated in the primary antibody overnight at 4°C. 
The coverslips were washed by dipping them gently in 1X PBS without Ca2+/Mg2+ and 
incubated in secondary antibody solution for one hour at 20°C. The coverslips were washed 
again in 1X PBS without Ca2+/Mg2+. Five L of prolong gold mounting medium (Thermo-
Fisher Scientific, Waltham, MA) was placed on a glass slide and the coverslips were 
mounted on it. Cells were imaged on the Olympus epifluorescence microscope at 20X 
magnification. Cells expressing neural markers were quantified using Image J software 
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(Version 1.6.0_65) and graphed. A detailed description of the primary and secondary 
antibodies is provided in Table 3 
 
Flow cytometry 
Cells grown in six-well plates and treated with conditioned medium were allowed to 
differentiate for four days. The cells were then detached as described above. The cells were 
collected in a microcentrifuge tube and centrifuged at 300xg. The supernatant was 
discarded and the cells were fixed using 100L/sample cytofix-cytoperm (Bd biosciences, 
Cat# 554714) solution for 30 minutes at 20°C. The cytofix-cytoperm solution was washed 
by adding 500L/sample perm-wash solution (BD biosciences Cat# 554723) and 
centrifuging at 300xg. The pellet was resuspended in 50L/sample primary antibody 
solution for 30 mins at 20°C. All antibody solutions were made by diluting stock solution 
in perm/wash buffer. The cells were washed with 500L/sample of perm-wash buffer and 
centrifuged at 300xg for 5 mins at 20°C. The cells were treated with secondary antibody 
for 30 mins at 20°C and washed with cytofix-cytoperm solution as the previous step. The 
pellet was resuspended in staining solution (3% FBS in 1X PBS). The cells were run 
through the flow cytometer using the gate to exclude debris as described in the single pulse 
BrdU assay protocol. Signals for neural markers were measured and the percent live cells 
were graphed. A detailed description of the antibodies is provided in Table 4. 
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Table 3 
Antigen Primary Antibody 
(Concentration, Supplier, Cat#) 
Secondary Antibody 
(Concentration, Supplier, Cat#) 
Nestin Mouse anti-Nestin (1:200; EMD 
Millipore, Cat# MAB353) 
Anti-mouse Alexa Fluor 488 
(1:1000; Thermo Fisher Scientific, 
A11034) 
BIII-tubulin Rabbit anti-BIII-tubulin (1:500; Cell 
Signaling Technology; Cat# 5568) 
 
Anti rabbit-Alexa Fluor 555 
(1:1000; Thermo Fisher Scientific, 
A21428) 
Doublecortin 
(DCX) 
Guinea pig anti-doublecortin 
(1:1000; EMD Millipore, Cat# 
AB2253) 
Anti guinea pig-Alexa Fluor 555 
(1:2000 Thermo Fisher Scientific, 
A11073) 
Microtubule 
associated protein 2 
(MAP2) 
 
Rabbit anti-MAP2 
(1:500, EMD Millipore Cat# 
AB5622) 
Anti rabbit- Alexa Fluor 555 
(1:1000; Thermo Fisher Scientific, 
A21428) 
Glial fibrillary acidic 
protein (GFAP) 
Rabbit anti-GFAP 
(1:500; DAKO, Cat# Z0334) 
Anti rabbit- Alexa Fluor 555 
(1:1000; Thermo Fisher Scientific, 
A21428) 
SOX2 Rabbit anti-SOX2 
(1:200; EMD Millipore, Cat# 
Ab5603) 
Anti-rabbit- Alexa Fluor 555 
(1:1000; BD biosciences, 558416) 
PAX6 Rabbit anti-PAX6 
(1:200 Covance, Cat# PRB-278P) 
 
Anti-rabbit-Alexa Fluor 555 
(1:1000; BD biosciences, 558416) 
Table 3: Antibodies for ICC. 
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Table 4 
Antigen Primary Antibody 
(Concentration, 
Supplier, Cat#) 
Secondary Antibody 
(Concentration, Supplier, 
Cat#) 
BD Accuri  
Channel 
Nestin Mouse anti-nestin-PE 
(1:50; RandD systems, 
IC1259P) 
- FL2 
SOX2 Rabbit anti-SOX2 
(1:50; EMD Millipore, 
Ab5603) 
Anti-rabbit-PE 
(1:100; BD biosciences, 
558416) 
FL2 
BIII-tubulin Rabbit anti-BIII-tubulin 
(1:50, Cell Signaling 
Technology Cat#5568) 
Anti rabbit-Alexa Fluor 488 
(1:100; Thermo Fisher 
Scientific, A11034) 
FL1 
DCX Goat anti-doublecortin 
(1:50; Santa Cruz 
biotechnology, sc-8066) 
Anti-goat-Alexa Fluor 647 
(1:100; Jackson 
immunochemicals, 705-605-
147) 
FL4 
 GFAP Rabbit anti-GFAP 
(1:50 DAKO, Cat# Z0334) 
Anti rabbit-PE 
(1:100; BD biosciences, 
558416) 
FL1 
Table 4: Antibodies for flow cytometric characterization of NSPCs. 
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In-cell Western (ICW) assay 
Neurospheres were passaged as described above. NSPCs were seeded in 96-well 
plates at 3386 cells/ well in NSPC growth medium. The cells were allowed to grow for 5 
or 7 DIV. On these days, the medium was removed and the cells were fixed with 4% PFA 
for 20 minutes and permeabilized using 0.2% Triton X-100 for 15 minutes. The plates may 
be stored in 1X PBS until further use. For ICW, the cells were blocked using 1:1 solution 
(odyssey buffer:PBS without Ca2+/Mg2+) of blocking buffer for 1 hour at 20°C. 
Concentration-matched isotype control antibodies (IgG) were also prepared in blocking 
buffer.  Primary antibodies were prepared in 1:1 blocking buffer at indicated concentrations 
and kept at 4°C until further use (Table 5). Blocking solution was discarded and primary 
antibody solution was added to the plates. The plates were incubated overnight at 4°C. 
Primary antibody solution was removed and the plates were washed twice with PBS. 
Secondary antibody solutions were prepared in 1:1 blocking buffer at indicated 
concentrations in Table 5. DRAQ5 (Biostatus Limited, Leicestershire UK; Cat# 
DR50050), a DNA intercalating probe, was added at a final concentration of 5 M (stock 
concentration 5mM) to the secondary antibody solutions at indicated concentration.  The 
secondary antibody solutions were added to the cells and incubated at 4°C for one hour at 
20°C. The secondary antibody solution was removed and the cells were washed twice with 
PBS. The plates were imaged on Odyssey Infrared Imaging System. Integrated 
fluorescence intensity values for each neural marker were normalized with the 
corresponding DRAQ5 values.  Normalized values for each neural marker were subtracted 
from its corresponding concentration matched isotype control values. The adjusted values 
 SEM of each marker were graphed using Microsoft Excel.   
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X. Statistical analyses 
Data are presented as the mean ± SEM from 3-4 technical replicates for all 
experiments.  For the neurosphere assay, a one-way ANOVA was performed. To compare 
the IFN-treated groups with the untreated group, a Dunnett’s multiple comparison test 
was applied.  For the BrdU assay and western blot analyses, a one-way ANOVA was 
performed and a Bonferroni multiple comparisons post-hoc test was applied for pair-wise 
comparisons between the untreated and IFN-treated groups. For the BrdU pulse-chase 
assay, a two-way ANOVA was performed to compare the differences between the different 
treatment groups across different time points, with Bonferroni multiple comparisons post-
hoc analysis. Flow cytometry data (BrdU incorporation and NSPC differentiation) as well 
as ICC data from conditioned medium treatment experiments were analyzed using two-
way ANOVA with Holm-Sidak post-hoc test for multiple comparisons. For the CFSE and 
TUNEL assays, a two-tailed Student’s t-test was applied for statistical comparisons. For 
all other assays, a one-way ANOVA was performed.  Differences were deemed significant 
when p ≤ 0.05. For p values between 0.0001 and 0.05, actual p values are reported.  For 
any values <0.0001, Graphpad software reports the values as “p<0.0001”, which we list as 
appropriate. All statistical analysis was performed using Graphpad Prism (Version 6.0b). 
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Table 5 
Antigen Primary Antibody 
(Concentration, Supplier, Cat#) 
Secondary Antibody 
(Concentration, Supplier, Cat#) 
Nestin Mouse anti-nestin 
(1:500; EMD Millipore, MAB353) 
IRDye 800CW Donkey anti-mouse 
(1:10000; Licor Biosciences, 926-
32213) 
Microtubule 
associated protein-2 
(MAP2) 
 
Rabbit anti-MAP2 
(1:500, Millipore Cat#AB5622) 
IRDye 800CW Goat anti-Rabbit 
(1:10000, Licor Biosciences, 926-
32211) 
 GFAP Rabbit anti-GFAP 
(1:1000 DAKO, Cat# Z0334) 
IRDye 800CW Goat anti-Rabbit 
(1:10000, Licor Biosciences, 926-
32211) 
Mouse Isotype 
control 
normal mouse IgG  
(1:200, Santa Cruz 
biotechnology, sc-2025) 
IRDye 800CW Donkey anti-mouse 
(1:10000; Licor Biosciences, 926-
32213) 
Rabbit Isotype 
control 
normal rabbit IgG  
(1:130 for GFAP, 1:200 for 
MAP2, Santa Cruz 
biotechnology, sc-2027) 
IRDye 800CW Goat anti-Rabbit 
(1:10000, Licor Biosciences, 926-
32211) 
Table 5:  Antibodies for ICW characterization of NSPCs.  
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Outliers were identified using the Grubb’s method and the alpha level was set to 
0.05 using Graphpad Prism. In the neurosphere assay for WT NSPCs, five outlier data 
points were reported corresponding to individual neurospheres. Upon statistical analysis of 
the cleaned data, the comparisons retained significance.  Technical replicates were obtained 
from at least 3 separate set of dissections. Each replicate was defined as embryonic cortical 
NSPCs from obtained from one female dam. Typically, each replicate involved NSPCs 
derived from 6-8 embryos. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 58 
Chapter 3: Assessment of the role of interferon-gamma signaling in neural 
stem/progenitor cell proliferation and differentiation 
 
I. Rationale 
Neural stem/progenitor cells (NSPCs) are multipotent cells in the CNS.  During 
CNS insults (viral infection, stroke, protein misfolding stress), the NSPC pool can expand 
or contract49,54,163-165. During many neurotropic infections, NSPC proliferation and 
neurogenesis declines51,166,167. These cytostatic responses by NSPCs may be attributed to 
direct infection by the virus and/or the anti-proliferative effect of inflammatory 
cytokines168,169. Our previous work demonstrated that neural cells display tailored cellular 
responses to IFN, depending upon the availability of JAK/STAT signaling molecules. For 
example, in primary neurons, IFN mediates control of MV infection. However, STAT1, 
which is the canonical transcription factor downstream of IFN, is not required for IFN-
mediated MV control. Moreover, STAT1 activation and expression is delayed in neurons 
unlike astrocytes, where it is activated immediately post-IFN treatment79. However, the 
effect of IFN on proliferation and cell cycle control of neural cells, and the resultant 
changes in neurodevelopment or differentiation, is largely undefined.  IFN is required for 
viral clearance of many neurotropic viral infections. IFN protected neurons from Sindbis 
virus-mediated cell death in a non-cytolytic fashion154. Similar observations have been 
made in IFN-mediated clearance of MV and hepatitis virus among others 61,170.  This is 
significant as mature neurons are largely a non-renewable cell type and control of virus 
without cell loss is imperative for effective protection of CNS functions.   Given the critical 
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role that IFN plays during CNS infections and the pluripotent effects of the cytokine of 
different neural cells, we examined IFN-mediated signaling pathways in primary NSPCs 
and the consequences on proliferation and survival.  
To study the effects of IFN on NSPC activity, we cultured NSPCs in vitro form 
E.12.5 embryos as has been described in Materials and Methods. For the purposes of this 
study, we wanted to elucidate the immune-mediated effects on growth and cell fate choice 
of NSPCs. Therefore, NSPCs were derived from E12.5 mice were used in order to provide 
sufficient cell numbers for experiments and to capture cells that were still in a proliferative 
state.  When cultured as a suspension, the NSPCs form clusters called neurospheres.  When 
cultured on poly-D-lysine/laminin-coated plates, the NSPCs will attach and grow as 
monolayers. The neurosphere culture system is used extensively as an in vitro model 
system to study neural development, proliferation, and self-renewal of NSPCs.  
Neurosphere cultures derived from E12.5 embryos also have been characterized in the 
literature. These neurospheres consist of a heterogeneous mixture of neural stem and 
progenitor cells and recapitulate the spatiotemporal characteristics of the developing CNS 
at that age171.  The neurosphere cultures, when dissociated and cultured as monolayers, 
differentiated into all the neural cell types depending upon culture conditions. Moreover, 
GABAergic and glutamatergic neuronal sub-types types were observed that formed 
functional synaptic connections. The NSPCs when allowed to differentiate, gradually 
differentiate into neuro and glioblasts and finally into terminally differentiated neurons and 
glia. Therefore, monolayer cultures may be used as effective tools to measure NSPC 
differentiation. To determine whether our NSPC cultures from CD46+ mice conformed to 
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the above observations, the cells were characterized to determine purity of the cells in both 
neurosphere and monolayer culture.  
 
II. Characterization of mouse E 12.5 NSPC: Neurosphere and monolayer cultures. 
Primary NSPCs can be cultured as neurospheres and monolayers. These models 
were used to answer specific questions pertaining to proliferation/cell cycle progression 
and differentiation, respectively. To understand the effects of IFN  on NSPCs, it was 
important to determine the cellular composition of NSPC cultures in vitro. Neurospheres 
(~150m in diameter) were formed by three days of growth in vitro (DIV3) in growth 
media designed to limit differentiation but maintain proliferative potential of the cells. 
After 3 DIV, the neurospheres were dissociated and the NSPCs were either plated as 
monolayers to measure neural markers by IFA/ICW, or grown in suspension again to 
determine neural marker and the IFN receptor. These experiments are described below in 
detail  
The expression of neural markers in monolayer cultures was determined. Post-
dissection, cortices were processed as described in materials and methods, NSPCs were 
cultured initially as neurospheres to expand the cell number for future experiments. On 
DIV3, the neurospheres were passaged and cultured as monolayers on poly-D-
lysine/laminin coated 24-well plates with coverslips for ICC (Figure 2), or 96-well plates 
for in-cell western assay (ICW, Figure 3). For ICC and ICW, the cells were grown for 
seven days and cellular purity was determined on DIV 3, 5, and 7 with ICC and on DIV 5 
and 7 with ICW.  
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On DIV 3, the monolayers had more than 90% of cells expressing nestin, whereas 
4% expressed MAP2 and, 1% cells expressed GFAP.  This cellular composition stayed 
consistent over 5 and 7 DIV. The expression levels of these markers also were quantified 
using ICW to measure the fluorescence intensity of each marker in the culture. The 
fluorescence intensity for each antibody was normalized against a nuclear stain (DRAQ5) 
to account for the total cell number in each well. Normalized ICW data showed that the 
cultures expressed low levels of MAP2 and GFAP on DIV 5, which is consistent with the 
ICC data. The levels of nestin increased over time from DIV 5 (0.030.05) to 7 (0.10.01). 
The expression of MAP2 increased on DIV 7 (0 to 0.020.001), but GFAP was not detected 
at any time point. This showed that that over time the composition of NSPC cultures 
remained constant, with very few terminally differentiated neurons or astrocytes.   
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Figure 2 
 
Figure 2: In vitro NSPC cultures contain low levels of differentiated neuronal and astrocytic 
cells.  NSPCs were grown in 24-well plates on poly-D-lysine/laminin coated coverslips.  The coverslips 
were collected on DIV 3, 5 and 7 fixed, permeabilized and co-stained for (A) Nestin (red) and MAP2 
(green), and (B) Nestin (red) and GFAP (green). Nestin+ (NSPCs), MAP2+ (neurons) and GFAP+ 
(astrocytes) cells were counted and graphed for all time points (C).  Green arrows denote 
differentiating neurons (MAP2+, top row) and astrocytes (GFAP+, bottom row). The total cell number 
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was counted using Hoechst as nuclear stain. Each cell type was quantified for all three time points in 
vitro and graphed as a percentage of total cells  SEM. Scale bar=100m 
 
NSPCs derived from E12.5 mouse telencephalons have been shown to express sex 
determining region Y-box 2 (SOX2) and Paired box protein (PAX6) in vivo and when 
grown as neurospheres172.  SOX2 and PAX6 are transcription factors that play an important 
role in the neural specification of ectodermal cells173 and maintain the proliferation of 
NSPCs once they differentiate from ectodermal lineage into the neural lineage174. Together, 
they coordinate the expression of genes such as Fgf4, Utf1, and Fbx15 that maintain NSPC 
proliferation and bring about CNS development175-177. Loss of SOX2 and/or PAX6 
decreases the clonogenicity of NSPCs, a measure of proliferative potential of the cells178. 
Therefore, to ascertain the purity of the NSPC cultures and the developmental stage of the 
stem cells, we co-labeled the NSPCs with nestin and SOX2 or PAX6. In the monolayer 
cultures, the NSPCs were found to be double-positive for nestin+/PAX6+ (Figure 4A) and 
nestin+/SOX2 (Figure 4B), suggesting that in nestin+ cells in our model are positive for 
the standard biomarkers of NSPCs.  
In order to study the effects of IFN on the NSPC cultures, we first determined 
whether the cells expressed the receptor for IFN (IFNR).   We measured the cell surface 
expression of IFNR1, one of the components of the heteroterameric receptor, on NSPCs 
using flow cytometry (Figure 5). IFNR1 was detectable on 81.6% of the cells in the 
neurospheres (Figure 5A). The neurospheres were comprised of a total of 95.3% nestin+ 
cells (Figure 5B), suggesting that some NSPCs may not express the receptor or may 
express the receptor at levels that are below the limit of detection of the assay. Twenty-five 
 64 
percent of the cells expressed both DCX, a marker for immature neurons, and the IFNR1 
subunit (Figure 5C).  Although we were not able to triple-label the cells for nestin, DCX, 
and IFNR1, we suspect that there is a subset of nestin+/DCX+ cells that represent cells 
transitioning from NSPCs to immature neurons, and that these developing cells express 
IFNR1.   No GFAP+/IFNR1+ cells were found (data not shown), which is consistent 
with the low to undetectable levels of GFAP found in the characterization studies.  
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Figure 3 
 
Figure 3: NSPC cell density and Nestin levels increase over time:  WT/NSPCs were seeded on Poly-d-
lysine/laminin coated 96-well plates at 3368 cells/well. Cells were grown in NSPC culture medium for 
(A) 5, or (B) 7 DIV and ICW assay was performed. Plates were fixed on DIV 5 or 7 and NSPCs were 
stained for (A and B, left panel) Nestin, MAP2, GFAP, and (A and B, right panel) DRAQ5. (C)  
Fluorescence values of neural markers were normalized against DRAQ5 and graphed for DIV 5 and 7. 
Data is presented as mean fluorescence (A.U)  SEM.   
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           Figure 4 
 
Figure 4: Monolayer cultures form E 12.5 CNS express classical biomarkers of NSPCs:  WT/NSPCs were 
seeded on Poly-d-lysine/laminin coated 24-well plates at 20,000 cells/well. Cells were grown in NSPC 
culture medium for 3 DIV. Plates were fixed and cells were stained for (A) PAX6 (red) and (B) SOX2 
(red). Both biomarkers were co-stained with nestin (green). Hoechst 33342 (blue) was used as nuclear 
marker.  Because PAX6 and SOX2 are transcription factors, staining for both proteins often appears in 
the nucleus, giving a pink color in areas of co-localization with Hoechst.   Scale bar=50m. 
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         Figure 5 
 
Figure 5.  Neurosphere cells express IFNR1.   Neurospheres were cultured for 3 days in vitro, 
dissociated into a single cell suspension, and stained for neural cell markers and for the R1 subunit of 
the IFN receptor (IFNR1).  Antibodies for IFNR1 (-IFNR1), the NSPC marker nestin (-Nestin), and 
the immature neuron marker doublecortin (-DCX) were used along with appropriate isotype controls. 
The cells were analyzed by flow cytometry and debris was excluded using the gate in (A). IFNR1 
expression was measured for NSPCs. (B). To co-label the neurosphere cells with the receptor and 
nestin or DCX, cells were stained for nestin and IFNR1 (C) or DCX and IFNR1 (D). Nestin+ cells were 
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also positive for IFNR1, and DCX+ cells were also positive for IFNR1. NSPCs (nestin+) and immature 
neurons (DCX+), are the predominant cell populations in the neurospheres. Co-labeling with nestin 
and DCX reveals that 55.2% of the nestin+ cells and 75.5% of DCX+ cells expressed IFNR1. 
 
III. IFN inhibits neurosphere growth 
As NSPCs express the IFN receptor, we reasoned that NSPCs would respond to 
elevated levels of IFN during a CNS infection, whether the cells were infected by the 
virus. Specifically, we hypothesized that IFN would decrease NSPC proliferation by 
inhibiting cell cycle progression. To determine the effects of IFN on NSPC activity, we 
subjected the NSPCs to IFN treatment. NSPCs were allowed to form neurospheres and 
NSPC diameter was measured as a marker of proliferation. Neurosphere diameter was 
significantly smaller in IFN-treated cultures in comparison to untreated cells or to cells 
treated with heat-inactivated IFN (ΔH IFN; 1000 U/ml) at all concentrations tested 
(Figure 6). These concentrations were chosen based upon physiological concentrations 
observed in vivo post MV administration179.  At DIV 3, IFN limited neurosphere diameter 
in comparison to untreated controls at both low (1 U/ml IFN) and high (1000 U/ml IFN) 
concentrations of IFN.  Neurospheres were restricted to 89.5%3.3 of untreated controls 
at 1 U/ml IFN (n=3, p=0.0063) and 59.4%3.0 of untreated controls at 1000 U/ml (n=3, 
p<0.0001) (Figure 6B).  By 7 days post-IFN treatment, neurosphere diameter was less 
than half of the untreated cells at 100 and 1000 U/ml of IFN (44.6%3.2 of untreated; 
n=3, p<0.0001 and 43.7%3.2 of untreated; n=3, p<0.0001, respectively).  These results 
show that IFN treatment was associated with a prolonged reduction in neurosphere 
proliferation.   
 69 
We next determined the distribution of neurosphere sizes during IFN treatment 
using a histogram analysis of neurosphere area.   We observed a decrease in median 
neurosphere area with IFN treatment (100 U/mL, DIV 5) as measured by the number of 
pixels2 in each neurosphere (Figure 6C).  The median neurosphere area was reduced 3-
fold from 2054.4 pixel2 in untreated cells to 656.5 pixel2 in IFN-treated NSPCs (100 
U/ml). 
Furthermore, the distribution of neurosphere sizes shifted toward a smaller-sized 
population of neurospheres with the addition of IFN, as shown by the leftward shift of the 
curve in the IFN-treated (100 U/ml) group (Figure 6C) versus untreated cells or cells 
treated with 1 U/ml IFN 
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Figure 6 
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Figure 6: IFN inhibits neurosphere growth in a concentration-dependent manner.  Wildtype NSPCs 
(WT/NSPCs) were treated with IFN (1-1000 U/ml) or with heat-inactivated IFN (ΔH IFN; 1000 U/ml) 
as a negative control for 3, 5, or 7 days in vitro (DIV). (A) Representative images of neurospheres 
imaged 5 days post-IFN treatment at 2x magnification for different concentrations of IFN (Scale 
bar=250 μm). (B) Quantitation of neurosphere diameter at 3, 5, and 7 days post-IFN treatment.  The 
longest diameter of each neurosphere was measured using Image J software. Data was collected from 
neurospheres in five fields/condition from three biological replicates and graphed as a percentage of 
untreated controls. Statistical analysis was applied by one-way ANOVA (** p<0.01, **** p<0.0001). (C) 
Histogram plots of neurosphere area for different concentrations of IFN on DIV 5 as measured by 
pixel2 for each neurosphere.   For each condition, five fields/condition were measured using cells from 
three biological replicates. Frequency distribution of the number of neurospheres corresponding to 
the indicated neurosphere area in pixel2 was plotted for each condition. 
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   Figure 7  
              
Figure 7: IFN restricts cell cycle progression in NSPCs and induces minimal apoptosis.  (A) TUNEL assay 
was performed on untreated and IFN-treated (100 and 1000 U/ml; 72h) NSPCs.  The average 
percentage of total TUNEL+ cells from 3 independent experiments is plotted with SEM (one-way 
ANOVA, ** p<0.01).  (B) WT/NSPCs were treated with IFN (1, 100, 1000 U/ml) for 72h and labeled 
with BrdU and 7-AAD.  The intensity of BrdU and 7-AAD staining per cell was assayed by flow 
cytometry.  Cell populations were gated in different phases of cell cycle (S = synthesis phase, G1= gap 
phase 1, M= mitosis phase, G2= gap phase 2). Representative plots for untreated and IFN-treated 
NSPCs (1000 U/ml) are shown. (C) Quantitation of NSPCs in each cell cycle phase.  The average 
percentage of cells in each cell cycle was plotted with SEM (n=3).  Statistical analysis was applied using 
one-way ANOVA (****p<0.0001; ***p<0.001). (D) Cells in the S-phase gates were analyzed for mean 
fluorescence intensity (MFI, arbitrary units, A.U.) of the BrdU signal for all treatment groups.  The MFI 
for the BrdU signal of IFN-treated cells was compared with untreated controls using a one-way 
ANOVA (*p<0.05). 
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IV. NSPCs proliferation is restricted at the G1/S checkpoint in response to IFN 
Based on the inhibition of neurosphere growth that we observed with IFN 
treatment, we reasoned that cell death and/or changes in the cell cycle could contribute to 
the reduction in neurosphere size.  IFN can induce apoptotic or pro-survival pathways 
depending on the cell type and on the context of other inflammatory mediators in the 
system 180-183.  To determine if apoptosis contributed to the IFN-mediated restriction in 
neurosphere size, we quantified the percentage of apoptotic cells in the neurospheres using 
the TUNEL assay (Figure 7A).  A significant but modest increase in apoptosis was seen 
at the highest concentration of IFN used in the study (0.45%0.08 TUNEL+ cells in 
untreated versus 3%0.5 TUNEL+ cells at 1000 U/mL IFN (n=4, p=0.0037), 
demonstrating that IFN can lead to limited cell death.   
We next performed BrdU/7-AAD staining in IFN-treated neurospheres to identify 
the stages of the cell cycle.  The thymidine analog BrdU is incorporated into newly 
synthesized DNA, which marks cells in the S (synthesis) phase of the cell cycle.  The cells 
are also counterstained with 7-AAD to measure the total DNA content 184.  We analyzed 
BrdU/7-AAD-stained NSPCs by flow cytometry, and gated single cells by cell cycle stage 
(representative plots are shown in Figure 7B).  With IFN treatment, there was a dose-
dependent decrease in the percentage of cells in the S-phase (48.8%1.0 untreated versus 
33.9%0.5 IFN-treated (1000 U/ml; n=4 p<0.0001)), suggesting that fewer cells were 
actively synthesizing DNA (Figure 7C, left panel).  Moreover, we observed a dose-
dependent increase in the number of cells in the G0/G1phase (38.7%1.0 untreated versus 
48.9%1.0 IFN-treated (1000 U/ml; n=4, p<0.0001)) and G2/M phase (0.36%0.1 
untreated versus 3.7%0.6 IFN-treated (1000 U/ml; n=4, p=0.001)) (Figure 7C, middle 
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and right panels respectively).  These findings indicate that IFN induces a major restriction 
in cell cycle progression at the G1/S checkpoint, and a significant, but relatively minor, 
restriction at the G2/M checkpoint.    
The changes in cell cycle progression could be explained by a longer G0/G1 phase 
and/or by a shorter S phase with IFN treatment.  To determine if IFN treatment also 
altered the duration of the cell cycle phases, we first compared the mean fluorescence 
intensities (MFI) of NSPCs in S phase (Figure 7D). The MFI of IFN-treated NSPCs in S-
phase was higher than the untreated group (n=4; p=0.0491 for 100 U/ml and p=0.0357 for 
1000 U/ml). Moreover, when comparing the number of BrdU+ cells in the G2/M phase, 
we found that the IFN-treated groups (100 and 1000 U/ml) had higher numbers of BrdU+ 
cells than the untreated control (Figure 7C), suggesting that more NSPCs were 
transitioning from the S phase to G2/M with IFN treatment. Together, these findings 
support the notion that IFN induces a shorter S phase in NSPCs.   
To further investigate IFN-mediated changes in the cell cycle progression, we also 
performed a BrdU pulse chase experiment. In this experiment, IFN-treated neurospheres 
(72h) were pulsed with BrdU for one hour and cell cycle progression was tracked in cells 
for nine hours post-BrdU washout (Figure 9) This allows the cells to complete one cell 
cycle and IFN-mediated effects can be detected by looking at the number of cells in each 
cell cycle phase over time.  At all time points, IFN treatment decreased the proportion of 
cells transitioning from G1 to S phase (G1/S) and from S-phase to G2 (S/G2) (Figure 9A 
and B).  However, the number of cells BrdU+ cells in the G0/G1 and G2/M phases 
increased with IFN treatment.  This observation corroborates the increased MFI of BrdU+ 
S-phase cells seen with IFN treatment (Figure 7D), suggesting that IFN leads to a 
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shortened S-phase.  These studies also suggest that IFN treatment lengthens the G0/G1 
phase, as the percentage of cells increased in G0/G1 in the presence of IFN.   
To directly test whether IFN controls the rate of proliferation, we conducted a 
CFSE proliferation assay. CFSE [5(6)-carboxyfluorescein diacetate succininyl ester] is a 
fluorescent dye that penetrates cell membranes, undergoes metabolism, and becomes 
trapped within the cell. During cell division, CFSE is equally distributed to daughter cells 
with fluorescence intensity decreasing by half with each cell division, thereby acting as a 
marker for the number of cell divisions that a cell has undergone. NSPCs were pulse-
labeled with CFSE and treated with IFN (100U/ml) for 2, 3, and 5 days.  IFN-treated 
NSPCs had higher mean fluorescence intensity (MFI) of the CFSE label (red lines, Figure 
9) in contrast to untreated control cells at all time points (black lines, Figure 9), which 
indicates that the untreated cells had progressed through more cell divisions during the 
same time period. The MFI of IFN-treated NSPCs was 1.3-fold greater than untreated 
cells at two days post-treatment (Figure 9, right panel) and 2-fold greater than untreated 
cells by five days post-treatment (Figure 9, left panel). Thus, IFN reduced the rate of 
proliferation by limiting the number of NSPC cell divisions over the 5-day time course. 
 
V. IFN alters activation and expression of STAT1 and STAT3 in NSPCs 
IFN primarily signals through the JAK/STAT1 pathway.  However, alternative 
signaling via STAT3 has also been reported 185, and activation of both STAT1 and STAT3 
has been demonstrated in primary hippocampal neurons after IFN stimulation 186. STAT1 
and STAT3 also are associated with inhibition and activation of cell proliferation, 
respectively 187-189.  Thus, based upon the cell cycle blockade observed in IFN-treated 
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NSPCs, we next analyzed the activation of STAT1 and STAT3 (Figure 10A). Both STAT1 
and STAT3 were phosphorylated upon IFN treatment (Figure 10B).  Phosphorylation of 
STAT1 on tyrosine 701 (Y701) and serine 727 (S727) was elevated in all IFN-treated 
groups, with phosphorylation of Y701 and S727 peaking at three days post-treatment when 
normalized to GAPDH (348-fold increase above untreated for Y701 and 184-fold above 
untreated for S727; n=3, p<0.0001). Phosphorylation of STAT3 was less pronounced than 
STAT1, with a 2.4-fold increase in phosphorylation versus untreated NSPCs at DIV 2 (n=4, 
p=0.0018), followed by a decline in phosphorylation below the untreated group by DIV 5.  
Basal levels of phosphorylated STAT3 also increased over time in the untreated groups 
(10-fold increase in phosphorylated STAT3 in the untreated group at day 5 versus day 0). 
We also observed an increase in the total expression levels of STAT1 and STAT3, 
regardless of phosphorylation status, in all IFN-treated groups. These findings indicate 
that NSPCs respond to IFN with a sustained activation of STAT1 and a transient, but 
significant, activation of STAT3. 
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Figure 8 
 
Figure 8:  IFN decreases NSPC cell cycle progression.  WT NSPCs were treated with IFN (100 U/ml) 3 
days or left untreated. On day 3, the cells were pulsed with BrdU for one hour. The BrdU was washed 
out and the cells were harvested at 0, 3, 6, and 9h post-washout. Cells were processed as described in 
materials and methods for BrdU/7-AAD staining.  (A) Representative plots for untreated (top row) and 
IFN-treated (1000 U/mL, bottom row) NSPCs with gates for G0/G1, G1/S, S/G2 and G2/M phases at 
different time points.  (B) Averages of cell percentages in the each of cell cycle gate were quantified 
for untreated, and IFN-treated (100 and 1000 U/mL) NSPCs.  Error bars represent SEM. Statistical 
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analysis was applied using two-way ANOVA with Bonferroni post-hoc analysis (n=3), * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001. 
 
Figure 9 
 
 
 
Figure 9: IFN  reduces proliferation rate in NSPCs. Untreated NSPCs were loaded with CFSE and treated 
with IFN (100 U/ml; red line) or were left untreated (black line). (A)  CFSE signal was measured by 
flow cytometry and assayed mean fluorescence intensity (MFI) on DIV 2, 3, and 5 post-IFN treatment. 
Representative histograms for each time point are shown. (B) The MFI for each condition was averaged 
and statistical analysis was applied using student’s t-test (*p<0.05; n=5).   
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Figure 10 
 
Figure 10: NSPCs activate STAT1 and STAT3 upon IFN stimulation. 
IFN-treated NSPCs (100U/ml) were collected on DIV 2, 3, and 5, and lysed for western blot analysis. 
(A) Representative blots are shown for phosphorylated STAT1 (Y701 and S727), total STAT1, 
phosphorylated STAT3 (Y705), and total STAT3. GAPDH is shown as the loading control.  (B) The 
fluorescence signal for each protein was quantified and normalized to GAPDH.   (C) For the 
phosphorylated STAT1 and STAT3 bands, the fluorescence signals were also normalized to the levels 
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of the total STAT1 and STAT3, respectively. The average of 3-5 biological replicates is plotted with SEM.  
Statistical analysis was applied using repeated measures one-way ANOVA with Bonferroni multiple 
comparisons post-hoc analysis (****p<0.0001, *** p<0.001, ** p<0.01 *p<0.5). 
 
We also observed an increase in the total expression levels of STAT1 and STAT3, 
regardless of phosphorylation status, in all IFN-treated groups. These findings indicate 
that NSPCs respond to IFN with increased expression of STAT1 and STAT3. 
Normalization of phosphorylated STAT1 and 3 with their respective total protein levels 
was also performed (Figure 10C).  The protein ratio of STAT1-P/STAT1 at both 
phosphorylation sites was consistent with that seen with GAPDH normalization.  However, 
the protein ratio of STAT3-P/STAT3 did not show increased activation with IFN at DIV 
2 or 3.  These data indicate that increased STAT1 activation is not only attributed to greater 
total STAT1 expression but also to increased activation of the STAT1 pathway. However, 
increased STAT3 phosphorylation corresponded with greater expression of total STAT3 
protein levels post-IFN treatment.  The STAT3 phosphorylation decreased on DIV5 with 
IFN treatment, while the total STAT3 expression continued to increase. This suggests that 
the NSPCs may be activating mechanisms that lead to decreased phosphorylation of 
STAT3, such as through (SOCS3) or protein tyrosine phosphatases (PTPs).  SOCS3 
prevents JAK-mediated STAT3 activation by inhibiting binding through the with tyrosine 
kinase SH2 domains190. PTPs remove phosphate groups from STAT3, thereby reducing 
activation191.  Thus, one possibility is that long-term IFN treatment leads 
dephosphorylation of STAT3 despite the elevated expression of the protein.   
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VI. IFN decreases site-specific phosphorylation of pRb and expression of late G1/S 
cyclin/cdk complexes 
Growth arrest is mediated by decreased expression of positive regulators of the cell 
cycle, including particular cyclins and cyclin-dependent kinases (cdks) depending on the 
cell cycle checkpoint.  In order to progress through the G1/S checkpoint, both cyclin 
D1/cdk4 and cyclin E/cdk2 phosphorylate the retinoblastoma protein (pRb) at serine 795 
(S795), which is a rate-limiting step in the progression from the G1 phase to the S phase 
192,193. Phosphorylation at S795 is critical for pRb inactivation and dissociation from the 
transcription factor, E2F1 194; whereas, phosphorylation at serine 807/811 (S807/811) is 
not required for progression to the S phase 195.  Because we observed that IFN restricted 
cell cycle progression at G1/S checkpoint, we next analyzed the protein expression of 
cyclin D/cdk4 (early G1 phase) and cyclin E/cdk2 (late G1 phase) complexes in NSPCs 
post-IFN treatment (Figure 11). Cyclin D1 expression did not significantly change after 
IFN treatment until DIV 5, where cyclin D1 levels increased transiently (n=4, p=0.0011).   
Cyclin D1 also undergoes cyclical changes in phosphorylation and subcellular localization 
196. This includes nuclear to cytoplasmic redistribution and phosphorylation, with the 
highest levels of phosphorylation occurring after the G1/S transition 197,198. Therefore, if 
IFN treatment slowed the transition of NSPCs into the S-phase, we would expect a 
decrease in the phosphorylated form of cyclin D1.  In Figure 5, the upper cyclin D band 
(open arrowhead) corresponds to the phosphorylated form of the protein; the lower band 
corresponds to the unphosphorylated form (closed arrowhead) (Figure 11A). When 
quantified separately, the phosphorylated form of cyclin D1 decreases in the IFN-treated 
groups at DIV 2 and 3, consistent with a G0/G1 restriction.  Cdk4 expression was also 
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unchanged in the presence of IFN (data not shown).  Expression of cyclin D3 decreased 
with IFN treatment only at DIV 3, suggesting that the regulation of expression of D-type 
cyclins do not play a major role in IFN-mediated control of cell cycle progression.  In 
contrast, the expression of both cyclin E and cdk2 decreased at all time points post-IFN 
treatment, suggesting that IFN acts at the late G1 phase. We also examined multiple 
phosphorylation sites on pRb (Figure 11B).  Expression levels of total pRb did not change 
with IFN treatment.  However, phosphorylation of pRb at S795 was decreased at both 
DIV 2 (2.25-fold decrease versus untreated) and DIV 3 (2-fold decrease versus untreated) 
with IFN treatment (n=4, p=0.0002), while S780 and S807/811 were not affected by IFN. 
In untreated NSPCs, pRb phosphorylation at each of the phosphorylation sites increased at 
DIV 2 and 3, and declined by DIV 5, suggesting that the untreated neurospheres undergo 
a period of sustained growth early in culture that slows by DIV 5.  Together, these results 
show that IFN interferes with G1/S cell cycle progression by decreasing the expression of 
cyclin/cdk complexes that control the late G1 phase transition, and ultimately decrease pRb 
phosphorylation.  However, the expression of early G1 phase cyclin/cdk complexes are 
unaffected by IFN. 
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Figure 11 
 
Figure 11 IFN modulates the expression of cell cycle checkpoint proteins and the phosphorylation of 
pRb in NSPCs. 
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(A) Expression of cyclins D1, D2, D3, E and cdk2 were measured using western blot and fluorescence 
signals were normalized to GAPDH as a loading control. For cyclin D1, the top band (open arrowhead) 
corresponds to the phosphorylated form of cyclin D1 and the bottom band (closed arrowhead) 
corresponds to the unphosphorylated form of cyclin D1. (B) Expression of total retinoblastoma protein 
(pRb) and associated pRb phosphorylation at different serine residues (S780, S795, and S807/811) was 
measured. The fluorescence signal for each band was normalized to GAPDH as a loading control. For 
pRb S795, normalization was also performed against total pRb. Quantitation of samples is shown as 
the average with SEM.  Statistical analysis was applied using repeated measures one-way ANOVA with 
Bonferroni multiple comparisons post-hoc analysis (****p<0.0001, *** p<0.001, ** p<0.01 *p<0.5; 
n=3-5). 
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VII. STAT1 is crucial for IFN-mediated inhibition of NSPC proliferation 
IFN induced an anti-proliferative phenotype in NSPCs that was characterized by 
strong, persistent STAT1 activation.  To study the role of STAT1 in IFN-induced growth 
arrest in NSPCs, we analyzed primary NSPCs from STAT1-KO mice, which express a 
truncated form of STAT1 that is devoid of the first three translated exons and is 
functionally deficient in the ability to bind to GAS elements 161.  The impact of IFN on 
NSPC proliferation was abrogated by the loss of functional STAT1 (Figure 12).  We first 
determined the diameter and area of STAT1-KO neurospheres treated with IFN.  
Neurosphere diameter was decreased at the highest concentration of IFN (1000 U/ml) 
(Figure 12B), but not at the other concentrations of IFN that had an impact on the growth 
of wildtype neurospheres (1, 10, and 100 U/ml, (Figure 12B).  At 1000 U/ml IFN, there 
was a 27% decrease in neurosphere diameter in STAT1-KO NSPCs (n=3, p<0.0001) as 
compared to a 53% decrease in the WT NSPCs at the same time point (DIV 5).  Histogram 
plots of the area of the STAT1-KO neurospheres showed that IFN treatment (1 and 100 
U/ml, (Figure 12C) reduced neurosphere area to a lesser extent than in wildtype NSPCs.  
The median area decreased from 2547.5 pixel2 in untreated STAT1-KO neurospheres to 
2247 pixel2 in neurospheres treated with 100 U/ml IFN; a 300 pixel2 decrease as compared 
to a 1400 pixel2 decrease in WT NSPCs.  Notably, the area of the untreated STAT1-KO 
neurospheres (2547.5 pixel2, DIV 5) was greater than untreated WT neurospheres (2054 
pixel2) at the same time point (Figure 6 and 12).  Moreover, the diameter in all treatment 
groups of the STAT1-KO NSPCs was greater than in the corresponding treatment groups 
of WT NSPCs (Figure 13), suggesting that deletion of STAT1 permitted greater growth 
of the neurospheres regardless of IFN treatment.  The higher growth rate of the STAT1-
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KO NSPCs limited data collection at DIV 7, as the larger neurospheres began to clump and 
settle at the bottom of the flask, with the appearance of a darker center by phase-contrast 
microscopy.  We suspect that the larger size of the STAT1-KO neurospheres prevented 
necessary growth factors and nutrients from reaching the cells located in the core at later 
time points.   
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Figure 12 
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Figure 12: STAT1 is required for IFN-mediated inhibition of neurosphere growth.  STAT1-KO NSPCs 
were treated with IFN (1-1000 U/ml) or with heat-inactivated IFN (ΔH IFN; 1000 U/ml) as a negative 
control for DIV 3 and 5 post-IFN treatment (A) Representative images of neurospheres imaged 5 days 
post-IFN treatment at 2x magnification for different concentrations of IFN (Scale bar=250 μm). (B) 
Quantitation of neurosphere diameter at 3 and 5 days post-IFN treatment.  The longest diameter of 
each neurosphere was measured using Image J software. Data was collected from neurospheres in 
five fields/condition from three biological replicates and graphed as a percentage of untreated 
controls. Statistical analysis was applied by one-way ANOVA (*** p<0.001, **** p<0.0001). (C) 
Histogram plots of neurosphere area for different concentrations IFN on DIV 5 as measured by pixel2 
for each neurosphere.   Frequency distribution of the number of neurospheres corresponding to the 
indicated neurosphere area in pixel2 was plotted for each condition. Note that the range of the x-axis 
is greater than in Figure 6C.   
 
 
 
 
 
 
 
 
 
 
 
 
 89 
Figure 13 
 
Figure 13: STAT1 loss leads to faster growth of neurospheres.   Absolute values of (A) WT and (B) STAT1-
KO NSPCs were graphed for controls (untreated, and H), and IFN-treated (1, 10, 100, 1000 U/mL) 
NSPCs at different time points. Data was collected from neurospheres in five fields/condition from 
three biological replicates and the diameters of all groups were compared with untreated group using 
one-way ANOVA and Dunnett’s post-hoc corrections. *p<0.05, ****p<0.0001.   
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Figure 14 
 
Figure 14: IFN-mediated regulation of cell cycle progression is STAT1-dependent in NSPCs.   (A) STAT1-
KO NSPCs were treated with IFN (1, 100, 1000 U/ml) for 72h and labeled with BrdU and 7-AAD.  The 
BrdU and 7-AAD intensities per cell were assayed by flow cytometry.  Cell populations were gated in 
different phases of cell cycle (S = synthesis phase, G1= gap phase 1, M= mitosis phase, G2= gap phase 
2). Representative plots for untreated and IFN-treated NSPCs (1000 U/ml) are shown. (B) 
Quantitation of NSPCs in each cell cycle phase.  The average percentage of cells in each cell cycle phase 
was plotted with SEM (n=3).  Statistical analysis was applied using one-way ANOVA (** p<0.01). 
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We also measured the cell cycle progression in STAT1-KO NSPCs during IFN 
treatment.  We found that the cytostatic effect in WT NSPCs was lost at all but the highest 
concentration of IFN (1000 U/ml) (Figure 14A and B).  There was no change in the 
number of cells in the S, G0/G1, and G2/M phases with 1-100 U/mL IFN treatment at any 
time point.  A modest effect was observed with 1000U/mL IFN, with only a 4%0.9 
decrease (n= 4, p=0.005) in S phase cells in STAT1-KO NSPCs as compared to 15%0.5 
decrease for WT NSPCs at the same concentration (Figure 14B).  These findings 
demonstrate that STAT1 mediates the cytostatic effect of IFN on NSPCs, though STAT1-
independent pathways may also contribute. Furthermore, there was no change in the 
proliferation rate of STAT1-KO NSPCs in the presence of IFN when measured by CFSE 
labeling (Figure 15). These findings demonstrate that STAT1 mediates the cytostatic effect 
of IFN on NSPCs, though STAT1-independent pathways may also contribute.  
IFN-treated WT NSPCs transitioned faster into the G2/M phase than untreated 
cells (Figure 6). This effect was not observed in the STAT1-KO NSPCs (Figure 14), 
where IFN did not affect the percentage of cells in G2/M.  However, when comparing the 
untreated controls of WT and STAT1-KO NSPCs, the latter had significantly higher cells 
in the G2/M phase. Collectively, these data indicate that STAT1 is responsible for 
mediating much of the anti-proliferative effects of IFN on NSPCs. However, STAT1-KO 
NSPCs may also be inherently cycling a faster rate than WT NSPCs, as indicated by the 
greater neurosphere sizes of untreated STAT1-KO cells.   
To compare the effects of IFN on cell cycle progression in NSPCs with other 
neural cell types, we also performed the BrdU assay on primary murine astrocytes in vitro. 
Astrocytes (Figure 16) were treated with IFN (100 U/mL) for 24 or 72 h. Cultures were 
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assayed by flow cytometry. In WT/astrocytes, IFN-induced a decrease in S-phase cells by 
72 h, but also caused a decrease in cells in G2/M phase and an increase in the percentage 
of cells in the resting G0/G1 phase (Figure 16A). Together, these results suggest that IFN-
induces a cytostatic effect in astrocytes, with fewer cells actively progressing through the 
cell cycle. To determine if STAT1 was responsible for the cytostatic effects of IFN in 
these cultures over time, astrocytes (Figure 16B) from STAT1-KO mice with IFN. In the 
absence of functional STAT1, IFN did not affect cell cycle progression in MEFs or 
astrocytes at either time point. Thus, the cytostatic effects of IFN are STAT1-dependent 
in astrocytes. 
 
VIII. STAT1 mediates the effects of IFN on pRb phosphorylation and cyclin/cdk 
expression 
We further explored whether the absence of STAT1 abrogated changes in the 
expression of cell cycle regulatory proteins.  Western blot analysis on STAT1-KO NSPCs 
showed that STAT3 activation increased at DIV 2 (Figure 17A; n=3, p<0.0001). IFN-
mediated STAT3 activation was greater in the absence of STAT1 than in WT NSPCs (10-
fold vs. 2.4-fold induction, respectively, on DIV 2).  Cyclin E expression was unaffected 
by IFN treatment at DIV 2 and 3, but increased at DIV 5, in contrast to WT NSPCs where 
cyclin E expression is reduced at all time points.  Cdk2 expression did not change at any 
time point. IFN treatment also did not alter the expression of cyclin D1 and D3, similar to 
WT NSPCs (Figure 17B).  The dephosphorylation of pRb at S795 seen in WT NSPCs was 
not observed with IFN treatment in STAT1-KO cells.  Rather, a significant increase in 
pRb S795 phosphorylation was observed on DIV 3 (Figure 17C; n=4, p=0.0406).  As with 
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WT NSPCs, the phosphorylation of pRb at S780 and S807/811 was unaffected in STAT1-
KO cells during IFN treatment.  Together, these studies further suggest that functional 
STAT1 is required for IFN-mediated modulation of cyclin E/cdk2 expression and pRb 
dephosphorylation during inhibition of cell cycle progression.     
 
IX. IFN reduces neuronal differentiation is NSPCs 
In addition to proliferation, altered NSPC differentiation may also play an 
important role in CNS development. IFN may induce differentiation into several cell types 
through the activation of the JAK-STAT pathway. Other signaling pathways such as the 
ERK1/2 signaling pathway may also play an important role in cellular differentiation. The 
role of IFN-activated STAT and other alternative pathways have been discussed in detail 
in the introduction. We wanted to determine whether differentiation in embryonic NSPCs 
was also affected by IFN. To study the same, NSPCs were grown as monolayers on poly-
d-lysine/laminin-coated coverslips.  Differentiation was induced in NSPCs by withdrawal 
of growth factors from the medium and the cells were treated with IFN or left untreated. 
Differentiation was measured using immunofluorescence assay (Figure 18). Two days 
post-IFN treatment, both neuronal and astrocytic differentiation was low (Figure 18A), 
with 6% of total cells expressing neuronal marker, MAP2; and 1.7% of total cells expressed 
the astrocytic marker, GFAP (Figure 18C). On day 2, neuronal differentiation did not 
change with IFN treatment remaining at 6%. The astrocytic differentiation increased from 
1.7 to 5% but was not statistically significant (p=0.6) (Figure 18B and C). On day 6 post-
IFN treatment, there was an overall increase in both neuronal and glial differentiation in 
comparison to day 2 (neuronal, 6% to 43% and astrocytic, 1.7 to 30%). However, in IFN-
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treated NSPCs, neuronal differentiation was significantly reduced (312.8%) whereas 
astrocytic differentiation increased (41.06 3.6%).   These data indicate that IFN increased 
NSPC differentiation into astrocytic lineage whereas decreased differentiation into 
neuronal lineage, likely through induction of the STAT1 signaling pathway.   
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Figure 15 
 
Figure 15: IFN-mediated decrease in NSPC proliferation rate is STAT1-dependent.  Untreated STAT1-
KO NSPCs were loaded with CFSE and treated with IFN (100 U/ml; red line) or were left untreated 
(black line).  (A) CFSE signal was measured by flow cytometry and mean fluorescence intensity (MFI) 
was calculated for each treatment group on DIV 2, 3, and 5 post-IFN treatment. Representative 
histograms for each time point are shown. (B) The MFI for each treatment group was averaged and 
statistical analysis was applied using student’s t-test (ns=not significant; n=5) 
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X. Discussion 
Characterization studies showed that both in neurosphere cultures and monolayers, 
more than 90% cells expressed nestin, which is a classical marker of NSPCs. The percent 
expression of the receptor for IFN, IFNR1 was also high (~82% of total neurosphere 
cells). Therefore, IFN may bind to the IFNR and NSPC are likely to respond to its effects. 
Almost one-third of the cells also expressed DCX, a marker of immature neurons, 
suggesting that a subset of the NSPCs were committing to a neuronal lineage. SOX2 and 
PAX6 co-expression with nestin also corroborates results from other studies that have 
defined the expression of stem cell markers in NSPCs derived from E. 12.5 mice172,178. In 
monolayer cultures, more than 90% of the cells expressed nestin.  They also expressed 
markers for mature neurons (MAP2) and astrocytes (GFAP).  However, both the number 
of cells and expression levels of mature neuronal and astrocytic markers remained below 
5%. Both ICC and ICW data indicated that the cells were highly proliferative with increases 
in cellular density and NSPC marker expression over time. Taken together, the 
characterization data indicates that our in vitro model mostly consisted of NSPCs with few 
fully differentiated mature neural cells. However, the high proportion of DCX expressing 
cells indicates that the NSPCs, although highly proliferative, are of a heterogeneous 
mixture of cells in varying stages of differentiation.  
We found that IFN inhibited NSPC proliferation as characterized by a decrease in 
neurosphere diameter and median neurosphere area (Figure 6). Cell cycle analysis showed 
that IFN restricted the transition of NSPCs into the S-phase and shortened the transition 
from S to the G2/M-phase (Figure 7).  We also observed a modest but significant increase 
in apoptosis at the highest concentration of IFN tested (1000U/ml).  Our results contrast 
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with studies on E14 NSPCs from C57BL/6J mice, where IFN substantially activated 
caspase-3/7 and only slightly decreased proliferation 199.  However, studies on striatal 
NSPCs from post-natal rats showed a similar increase in TUNEL+ cells with IFN 
treatment (~2-fold increase above untreated controls), albeit with a higher basal level of 
apoptosis in untreated neurospheres (15% TUNEL+ cells versus 0.5% TUNEL+ cells in 
our experiments, (Figure 7) 140. The cytostatic effects we observed are also consistent with 
other studies on E14 NSPCs from BALB/c mice and on post-natal day 2 and adult murine 
NSPCs from the subventricular zone, where IFN was shown to inhibit NSPC proliferation 
141,156.  Thus, whether IFN induced a cytotoxic or cytostatic effect on NSPCs may be 
dependent, at least in part, on the stage of development during which the NSPCs are 
harvested or on differential susceptibility of NSPCs in different brain regions.    
BrdU-labeling demonstrated a major restriction in the G1 phase of the cell cycle in 
the presence of IFN (Figure 7).  In the G1 phase, hypophosphorylated pRb binds to the 
transcription factor E2F1, which prevents nuclear translocation of E2F1 and in turn inhibits 
E2F1-mediated gene expression of other cell cycle regulators 200.  The C-terminal domain 
of pRb is sequentially and differentially phosphorylated at specific amino acid residues by 
cyclin/cdk complexes, which then regulate pRb-E2F1 binding.  We observed only transient 
changes in cyclin D1 and D3 expression and no changes in cdk4 expression at all time 
points following IFN treatment (Figure 8). These cyclin/cdk complexes control the early 
G1 phase checkpoint 201, which suggests that IFN does not restrict cell cycle progression 
at the early G1 phase.  In contrast, the cyclin E/cdk2 complex controls the late G1 phase 
checkpoint 201. IFN reduced cyclin E and cdk2 expression at all time points examined 
(Figure 8), suggesting that IFN acts at the late G1 phase in NSPCs, prior to entry into S 
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phase.  IFN also caused a minor restriction in G2/M phase (Figure 7), which may be due 
to early exit from S phase or delayed exit from G2/M.  In conjunction with the moderate 
increase in TUNEL+ cells (Figure 7), these data suggest that DNA damage signaling 
pathways may be activated at high concentrations of IFN.  Induction of DNA damage 
signaling has been noted in other cell types during IFN treatment, with similar effects on 
apoptosis and G2/M arrest 202,203.  
pRb phosphorylation at S795 is necessary for disruption of pRb-E2F1 binding 
192,194.  Consistent with reports in human fibrosarcoma cells, we found that IFN led to 
dephosphorylation of pRb at S795 121.  In primary cortical neurons, phosphorylation of pRb 
at S795 is also associated with cell death in a model of HIV-induced neurotoxicity 204.  
Thus, the low levels of apoptosis (~3%) seen in IFN-treated neurospheres may have been 
limited because of the loss of phosphorylation at S795.  We did not observe any effect on 
other pRb C-terminal phosphorylation sites (S780 and S807/811) (Figure 11).  This is 
consistent with previous studies that show the S807/811 residues are important for binding 
to the proto-oncogene c-Abl, but do not implicate them in affecting pRb binding with E2F1 
182.  pRb is also phosphorylated at S780 by the cyclin D1/cdk4 complex but not by the 
cyclin E/cdk2 complex 205,206.  Therefore, the lack of change in phosphorylation of S780 
by IFN at any time point further reinforces the role of cyclin E/cdk2 in mediating effects 
of IFN.  
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Figure 16 
 
Figure 16: STAT1 is required for IFN-mediated decrease in cell cycle progression in astrocytes.  Primary 
(A) WT and (B) STAT1-KO astrocytes were treated with IFN (100 U/ mL) for 24 or 72 h. Stages of the 
cell cycle were measured by BrdU assay. Samples were then assayed by flow cytometry. Experiments 
with cells from individual dissections were averaged (n = 3–4) and plotted with SEM. Statistical 
significance was assessed via paired t-test (*p < 0.01). 
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Figure 17 
 
Figure 17: IFN activates STAT3, but does not inhibit cyclin E expression or pRb phosphorylation at S795, 
in the absence of STAT1.  STAT1-KO NSPCs were treated with IFN (100U/ml) and collected on DIV 2, 
3, and 5 for western blot analysis. Representative blots for phosphorylated and total STAT3 (A); cyclins 
D1, D2, D3, E and cdk2, (B); and for total pRb and associated pRb phosphorylation sites (C) are shown.  
Signal intensity for each band was normalized to GAPDH as a loading control.  Quantitation of signal 
intensity is shown as the average from 3 independent biological replicates with SEM.  Statistical 
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analysis was applied using repeated measures one-way ANOVA with Bonferroni multiple comparisons 
post-hoc analysis (*p<0.5, **** p<0.0001). 
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IFN mediates unique signaling pathways in neural cells depending upon the 
availability of intracellular signaling molecules.  Our previous work has shown that 
astrocytes express relatively high levels of endogenous STAT1 and respond to IFN with 
rapid but transient STAT1 phosphorylation 79.  IFN also blocks cell cycle progression in 
the G0/G1 phase in astrocytes in a STAT1-dependent manner, with minimal induction of 
apoptosis 123.  In contrast, primary hippocampal neurons express low endogenous levels of 
STAT1, which is associated with delayed but sustained engagement of JAKs with IFNR 
and prolonged STAT1 phosphorylation 186,207.  IFN also induces protective signaling 
pathways in neurons that are STAT1-independent.  Similar to neurons, NSPCs express low 
basal levels of STAT1, and STAT1 expression and activation is sustained (over 72h) after 
IFN treatment.  However, IFN induces similar cytostatic effects in astrocytes and NSPCs 
that are STAT1-dependent, despite different kinetics of STAT1 expression and activation 
(Figure 15).  Thus, STAT1 is central to the anti-proliferative effects of IFN in neural cells, 
although the profile of STAT1 activation is not predictive of changes in cell cycle 
progression.  IFN also inhibits neuronal differentiation through the JAK/STAT1 pathway, 
suggesting that STAT1 activation is likely to impact on multiple aspects of NSPC function 
147.   
STAT1-KO NSPCs show a minor but significant decrease in neurosphere diameter 
and BrdU incorporation at the highest concentration of IFN tested (1000 U/mL) (Figure 
13).  This result could be attributed to residual STAT1 activity in the STAT1-KO mouse 
model (the truncated STAT1 protein retains 2% of DNA binding activity compared to full 
length STAT1) 161.  Nevertheless, we observed that a functional loss of STAT1 abrogated 
most of the cytostatic effects of IFN.  In cells lacking STAT1, IFN caused increased 
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phosphorylation of pRb on S795 as opposed to the dephosphorylation at S795 seen in the 
WT NSPCs.  STAT1-KO NSPCs also did not reduce cyclin E/cdk2 expression in response 
to IFN, but instead increased expression of cyclin E.  These observations indicate that the 
effects of IFN on proliferation, pRb phosphorylation, and cyclin/cdk expression are 
dependent on STAT1 (Figure 16).  
In the absence of STAT1, IFN induced greater STAT3 activation as compared to 
WT NSPCs. STAT3 can function as an alternative signaling pathway in response to IFN, 
as has been observed in embryonic fibroblasts 185.  Moreover, STAT1 and STAT3 show 
opposing effects on cell proliferation; STAT1 being anti-proliferative and STAT3 being 
pro-proliferative 187,189.  STAT1 inhibits cell proliferation in epithelial carcinoma cells 
through the upregulation of cyclin-dependent kinase inhibitors such as p21 and p27, and 
primary rat NSPCs upregulate p21 in response to IFN 168,208-210.  Conversely, heightened 
STAT3 expression and activation has been observed in B-cell lymphomas, which increases 
proliferation and survival 211.  The substantial increase in STAT3 activation in STAT1-KO 
NSPCs could also explain the enhanced neurosphere growth compared to WT NSPCs 
(Figure 13).  Therefore, it is possible that the absence of STAT1 leads to a loss of cell 
cycle inhibitory proteins, such as p21, as well as compensatory changes in other signaling 
pathways (e.g. STAT3), leading to greater cell cycle progression and more rapid 
neurosphere growth. 
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Figure 18 
 
Figure 18.  IFNγ inhibits neuronal differentiation. Effect of IFNγ on NSPC differentiation was studied by 
treating NSPCs with 100U/mL IFNγ and staining the cells for Nestin (NSPCs), MAP2 (neurons), and GFAP 
(astrocytes). (A and B) show the effect of IFNγ on neuronal and astrocytic differentiation at different 
time points respectively. On 2 days post-IFNγ treatment, both neuronal and astrocytic differentiation 
was low in untreated and IFNγ-treated groups. Differentiation into both lineages increased at 6 days 
post-IFNγ treatment. However, with IFNγ treatment there was significantly higher astrocytic 
differentiation and lower neuronal differentiation as compared to untreated control.  (C) Quantified 
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results of panels A and B. ** p<0.01 *p<0.05 vs. untreated; two-way ANOVA with Sidak’s multiple 
comparison’s test.  
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Besides IFN, other cytokines signal through the JAK/STAT pathway and are 
expressed during neurodevelopment and immune activation.  Cytokines such as ciliary 
neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) maintain the NSPC pool 
and initiate glial differentiation in vivo through the STAT3 pathway 212,213.  Acute maternal 
administration of IL-6 in pregnant mice increased NSPC number in the forebrains of adult 
offspring and resulted in perturbations in the localization of NSPCs in the SVZ and cortex 
214.  In this study, we describe the STAT1-dependent role of IFN in controlling NSPC 
proliferation, which not only supports recent studies on NSPCs in the adult SVZ138,141, but 
also identifies a mechanism for mediating NSPC cell cycle control.  However, an 
outstanding question is how the inflammatory cytokine milieu would affect NSPC 
function.  Since IFN, IL-6, and other inflammatory cytokines may be expressed 
concurrently during an anti-viral immune response, NSPC proliferation may be dictated by 
multiple signals. Moreover, IFN itself induces expression of multiple chemokines in adult 
NSPCs in vitro with downstream effects on differentiation 136.  Further studies to explore 
the combinatory effects of multiple cytokines will be necessary to fully understand how 
NSPCs respond to an inflammatory environment.  
This was the first study that describes STAT1-mediated control of pRb in the NSPC 
cell cycle.  Our data show that IFN-mediated activation of STAT1 may directly or 
indirectly control pRb activity in NSPCs, and suggests that immune mediators can affect 
NSPC growth and the phosphorylation status of pRb.  Further studies are necessary 
determine whether IFN mediates similar effects on NSPCs in the context of an anti-viral 
immune response in vivo, and whether communication between NSPCs and other brain 
cells by exchange of IFN-rich extracellular vesicles influences the anti-proliferative 
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response 215. Moreover, the long-term impact of alterations in NSPC proliferation on the 
infected host remains to be explored.  Our studies, and others like them, underscore the 
importance of considering the influence of the immune response in developing CNS tissue 
and whether inflammatory mediators bear upon neurodevelopmental disorders.   
We also determined whether IFN affected differentiation in NSPCs derived from 
embryonic mice (Figure 18). We observed reduced neuronal and increased astrocytic 
differentiation. Studies in adult NSPCs treated with IFN increased neuronal 
differentiation216. However, Pereira et al have observed that intraventricular administration 
of IFN  lead to a decrease in neuronal differentiation and neurogenesis138. These data, in 
addition to our observations, indicate that NSPC response to IFN is different at different 
stages of neurodevelopment. Moreover, direct effects of IFN on NSPCs may be different 
than indirect effects. IFN, may also activate immune cells in the CNS. These cells may in 
turn affect NSPCs proliferation and differentiation. Currently, our results do not reflect the 
effects of other immune cells. Therefore, these may have to be considered in designing 
future experiments.  
Our model focuses on the effects of anti-viral cytokines on uninfected NSPCs 
because many CNS viruses show tropism for neurons and other neural cells over NSPCs 
(e.g. herpes simplex viruses, measles viruses, Human Immunodeficiency Virus).  Thus, an 
outstanding question is how the cytokine milieu would affect NSPCs that are concurrently 
infected, as would be seen in many cases of CMV and ZIKV infection.  A number of DNA 
and RNA viruses encode proteins that target critical cell cycle regulators to achieve cellular 
conditions that are beneficial for viral replication. Many DNA viruses induce quiescent 
cells to enter the cell cycle, which is thought to increase pools of deoxynucleotides and 
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facilitate replication of viral genomes.  Human papilloma virus (HPV), Adenoviruses (Ad), 
and polyomaviruses such as the Simian virus 40 (SV40) drive cells in to the S-phase 217. 
The E6 and E7 protein of HPV up-regulate the expression of cyclins A, B, and E and  
inhibits cyclin D1 expression, which is important in the Rb pathway218. In contrast, some 
viruses can arrest cells in a particular phase of the cell cycle that is favorable for replication 
of a specific virus. Cell cycle arrest may inhibit early cell death of infected cells, allow the 
cells to evade immune defenses, or help promote virus assembly. For example, JEV inhibits 
G1 to S-phase cell cycle progression by decreasing cyclin D1 expression in NSPCs219.  
ZIKV and Sindbis virus also decreases cell cycle progression of NSPCs by forcing the cells 
into an apoptotic pathway220.  MV causes decreased T-cell proliferation though cell cycle 
arrest in the G0/G1 phase through decreased cyclin D1 and E expression.  Together, these 
studies demonstrate that viruses have differential effects on cell cycle progression 
depending on the target cell and the eventual benefit for survival and propagation of the 
virus.  This leads to the question of the how IFN-mediated effects on cell proliferation 
would play out in a virally infected cell.  The data presented here suggests that IFN 
decreases NSPC proliferation by decreasing the expression of cyclin/CDK complexes and 
retinoblastoma protein phosphorylation. As discussed above, these mechanisms are also 
targeted by certain viruses.  Therefore, the answer to the question would depend on what 
mechanism the virus employs when it infects NSPCs.  If the inherent mechanism employed 
by the virus is to increase NSPC proliferation, then IFN would counter the same. 
However, those viruses that also inhibit cell cycle progression and thus proliferation, IFN 
would further contribute to this effect.  The overall implication would also depend on the 
signaling mechanism that is activated by IFN in each cell type. For MV, previous data 
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from our lab showed that neurons control MV infection through a IFN-dependent 
mechanism. However, this viral control is not achieved through the canonical STAT1 
signaling mechanism in neurons. IFN also confers a neuroprotective effect on primary 
neurons, which is independent of STAT1 and dependent upon Extracellular-regulate 
kinase-1/2 (ERK1/2).  Here, our data suggests that IFN inhibits proliferation in NSPCs 
and astrocytes in a STAT1-dependent manner.  Thus, neural cells are not monolithic in the 
signaling pathways and phenotypic responses that are induced by a single cytokine.  These 
observations highlight the importance of the responding cell type in dictating the outcome 
of cytokine signaling and the diversity of pathways that can invoked by IFN.  
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Chapter 4: Effects of neuron-microglia interactions on NSPC activity 
I. Rationale 
Microglia, as the resident immune cells of the brains, play important roles in the 
healthy and diseased CNS. They comprise 10–15% of all CNS cells in the adult brain, and 
are found interspersed throughout the brain parenchyma. In vivo studies in healthy brains 
reveal that microglia are constantly in motion, surveying their microenvironment and 
communicating with neurons and other glia through direct contact with their cellular 
projections. They play a major role in maintaining homeostatsis in the adult CNS by 
releasing trophic factors such as nerve growth factor (NGF), brain-derived neurotropic 
factor (BDNF), glial cell-line derived neurotrophic factor (GDNF), ciliary neurotrophic 
factor (CNTF) and neurotrophin-3 (NT3), which mediate axonal growth221-224. These 
functions include phagocytosis of apoptotic neurons, synaptic pruning, and general 
immune surveillance (reviewed in 225).Microglia also influence neurogenesis axonal 
growth though the release of factors such as insulin-like growth factor-I and BDNF226,227.  
Microglia also affect NSPC activity during embryonic and neonatal brain development.  
Microglial cells colonize the developing cerebral cortex of prenatal and postnatal macaques 
and rats, phagocytosing NSPCs as neurogenesis nears completion228. Moreover, it was 
observed that phagocytosed NSPCs were not apoptotic (negative for TUNEL reactivity and 
cleaved caspases). The authors concluded that during CNS development, excess NSPCs 
were produced and these were eliminated by microglia228,229,  Moreover, microglial 
activation by LPS administration in pregnant rats decreased the NSPC numbers  (PAX6+) 
and numbers of newly differentiated neurons (TBR2+) in the embryos228. Therefore, 
 111 
microglia play varying roles in both CNS development and maintenance of normal 
functions once the CNS is formed.  
Considerable research has been conducted in several diseases states to determine 
the role of microglia in disease progression or protection against pathogenesis. Microglia 
are activated in both acute and chronic neuroinflammatory diseases.  In acute CNS injuries 
such as stroke, depletion of microglia during ischemia leads to exacerbation of injury 
characterized by increased infarct size, inflammatory cytokine release, and  
neurodegeneration230. Increased microglial activation is noted in traumatic brain injury, 
where activation was not only present in lesioned areas but also in areas remote to the focal 
damage231. This finding implies that inflammatory mediators released from injured cells 
affect healthy cells in the vicinity of the injured cells and in other distal parts of the brain. 
Studies have also shown that activated microglia play a significant role in the course of 
neurodegenerative diseases such as Parkinson’s Disease, through the release of toxic 
inflammatory mediators232-234. 
There is ample evidence that microglia are activated in neurotropic infections in the 
CNS.  HCMV infections of the CNS can cause severe neurodevelopmental deficits. 
Microglia are permissive to hCMV infections, but do not show signs of productive 
infection or cytopathic changes18.  hCMV-infected astrocytes secrete chemokines, 
primarily CCL2/MCP-1, that recruit microglial cells to the area of infection235. The 
microglial cells, but not astrocytes, produce the antiviral cytokine TNF-, which 
suppresses hCMV replication in astrocytes18.  In utero infection with MCMV leads to 
increased microglial activation in the fetal CNS along with infiltration of peripheral 
immune cells236. HSV-1 causes a CNS infection in neonates and immunocompetent adults, 
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which results in acute focal necrotizing encephalitis. Microglial cells in HSV-1 brains 
express elevated MHC class I and class II molecules and have a wide distribution 
throughout the brain, including areas distinct from the productive infection237. Increased 
microglial activation resulted in increased TNF-α and IL-1β expression from these cells. 
Both TNF-α and IL-1β are known to cause increased NSPC differentiation and affect their 
proliferation238,239.   Similarly, BDV infection is associated with microglial activation and 
release of pro-inflammatory cytokines such as IL-1β, TNF-α, and IFN. However, when 
the mice were treated with ribavirin, an antiviral agent, there was reduced microglial 
activation, a decrease in the expression of pro-inflammatory cytokines and improvement 
in body weight and clinical score87. These examples show that microglia are important 
mediators of the host immune response against viruses, which involves the release of 
proinflammatory cytokines and chemokines that may also cause bystander effects on 
neighboring cells. 
The cytokines released during a viral infection can bind to any cell expressing the 
cognate receptor, regardless of whether the cell is infected. NSPCs express a wide array of 
chemokine receptors, which likely means that the NSPCs would respond to the 
inflammatory milieu. Because microglia are a major producer of inflammatory cytokines 
during viral infections in the brain, it is likely that microglia produce factors that impact on 
NSPC function.  Shigemoto-Mogami et al found that inhibition of basal microglial 
activation using minocycline decreases the number of proliferative cells in the developing 
brain. Moreover, the decline in the pool of NSPCs and young neurons correlated with 
depressed levels of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6.  The levels of 
anti-inflammatory cytokines (IL-4 and IL-10) remained unchanged. This suggested that a 
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basal activation level may be necessary for homeostasis and normal development of CNS. 
Butovsky, et al observed that NSPCs co-cultured with differentially activated microglial 
in vitro induced opposing effects on NSPCs. LPS-activated microglia inhibited 
neurogenesis, whereas co-culture with IFN- or IL-4-activated microglia increased 
neurogenesis240. Thus, the effect of microglia on NSPC activity may depend on the type of 
insult or stimuli received by the microglia and the pool of cytokines released by the 
microglia. Moreover, Carr et al observed that co-culturing microglia with HSV-1-infected 
NSPCs reduced the loss of newly differentiated neurons. This protection is afforded by IL-
6 secreted by the microglia54.  This finding demonstrates that microglia can be protective 
during CNS infections through the release of cytokines.  These studies highlight the need 
for a better understanding of the interaction between microglia and NSPCs during viral 
CNS infections.  
In this chapter, we establish an in vitro model system to define the interactions 
between infected CNS neurons, responding microglia, and the ultimate impact on NSPC 
function.  Using the CD46+ model of neuron-restricted MV infection, we infect primary 
hippocampal neurons with MV in a co-culture with primary microglia.  Supernatants with 
secreted factors from the neuron/microglia co-culture are applied to monolayers of primary 
NSPCs.  We found that the MV-infected neuron/microglia co-cultures led to an increase in 
neurogenesis and a loss of pluripotency in the NSPCs, which was not observed with 
infected neurons alone or uninfected neuron/microglia co-culture supernatants.  
Surprisingly, there was not a significant effect of NSPC proliferation or cell cycle 
progression, suggesting that the microglia may not be dominate producers of IFN or may 
produce other cytokines that maintain NSPC growth.   These results suggest that microglia 
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respond to infected neurons in such a manner that encourages the differentiation of new 
neurons from uninfected NSPCs. 
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Figure 19 
               
Figure 19: Measles virus (MV) infects mature neurons but spares nestin expressing neural 
stem/progenitor cells (NSPCs). Sagittal brain sections from MV-infected CD46+ pups were collected 10 
days post-infection and stained for (A-I) MV (red) and nestin (green) or (J-L) MV (red) and NeuN 
(green). Representative images were taken using the Olympus epifluorescence microscope in different 
areas of the brain; (A-C) Thalamus and, (D-F) CA1 region of the hippocampus. (G-I) Fiber tracts of the 
medial forebrain bundle system. Magnification: 20X and scale bar: 50 μm. (J-L) Dentate gyrus of the 
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hippocampus. Magnification: 40X and scale bar: 25 μm. All sections were also stained with the nuclear 
stain, Hoechst (blue)  
 
II. Neuron-Microglia co-culture model 
There is ample evidence in the literature of crosstalk between microglia and 
infected or damaged neurons or NSPCs241,242. However, there are few studies that address 
the communication that occurs between infected neurons, microglia, and the resultant 
message that is delivered to NSPCs. One could hypothesize that the interaction between 
activated microglia and infected neurons affect NSPC proliferation and differentiation.  To 
address this question, we take advantage of a mouse model of neuron-restricted measles 
virus (MV) infection (CD46+ mice). The CD46+ model is discussed in detail in chapter 1. 
Briefly, in this model, MV selectively infects neurons as the human CD46 receptor is only 
expressed on mature neurons of the central nervous system, while NSPCs are spared from 
the infection (Figure 19).  To demonstrate if mature neurons are selectively infected by 
MV and NSPCs are spared from infection, CD46+ mice were infected intracranially with 
MV and the brains were harvested. Brain sections from the thalamus (Figure 19 A-C), 
CA1 region (Figure 19 D-F) and the dentate gyrus of the hippocampus (Figure 19 G-I) 
were stained for MV (Figure 19 A, D, G) and nestin (Figure 19 B, E, H).  No co-
localization of MV and nestin was observed in any regions of the brain.  On the other hand, 
staining for NeuN (marker for mature neurons) co-localized with MV. These results 
demonstrate that NSPCs are spared from infection and only mature neurons are infectable 
with MV in CD46+ mice. Additionally, ICC was performed to ensure that MV selectively 
infected neurons in vitro. MV also selectively infected neurons in vitro with consistent co-
localization observed for MV and MAP2 staining (Figure 21). 
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To determine the effects of neuron-microglia interactions on NSPC activity, 
primary neurons were derived from E. 15.5 mice and co-cultured with primary microglia 
isolated from postnatal day 1-2 mice. The CD46+ neurons  have been extensively 
characterized  in vitro by Rall et al243.  Neurons were infected with MV-Edmonston strain 
at multiplicity of infection (MOI) of 1 and the extent of infection increased with time.  At 
1 day post-infection (dpi), a low proportion of neurons (5% or less) showed evidence of 
MV antigen, but by 3 dpi the proportion of infected cells averaged 10 to 20% (Figure 21). 
Extracellular virus is not produced and the virus spreads through transynaptic spread 
between the neurons without formation of syncytia (Figure 21). Thus, the microglia and 
NSPCs do not become infected with MV in this model.  A schematic of the co-culture 
model and timeline of experiments is depicted in Figure (20 A and B). In the co-cultures, 
microglia were positive for the marker IBA-1, a calcium binding protein that stains 
microglia in vitro and in vivo. The morphology the microglia was also was similar to 
previous studies of in vitro microglial cultures244. The neurons are plated first to allow for 
attachment and the formation of synapses between the neurons. After 4 days in vitro, the 
neurons are infected with MV and incubated for 3 days to allow the infection to spread 
through the culture.  At 3 dpi, the microglia were purified from a mixed glial culture and 
added to the infected neuron cultures.  Four days later, the supernatant from the 
neuron/microglia co-cultures was removed and applied to the NSPC cultures and incubated 
for 4 more days to allow for changes in differentiation and growth.   
Microglia comprise 10-15% of the cells in the CNS, with a neuron to glia ratio of 
3:1 245. To mimic the cellular ratio found in the brain, microglia were plated at 25,000 and 
100,000 cells/well in 24-well and 6-well plates respectively in the co-culture. The CD46+ 
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neurons were cultured at 250,000 cells/well for 24-well plates and 1,000,000 cells/ well for 
6-well plates.  One drawback of this model is that we do not include astrocytes in the 
system, which are a major component of brain tissue.  However, our goal is to dissect how 
the microglia react to infected neurons, and how subsequent signals from the microglia 
influence the NSPCs.  We observed that in co-cultures with MV-infected neurons, there 
were higher number of microglia that had assumed an amoeboid shape. In the uninfected 
cultures, there were higher numbers of microglia with a rounded smaller morphology 
(Figure 22). Whether the amoeboid microglia have higher activation state or an M1/M2 
phenotype is unknown.  However, other glial cells, such as astrocytes, also develop an 
amoeboid morphology under stress (such as co-incubation with infected neurons)246.  
Peripheral monocytes also assume a flatter, more amoeboid morphology when migrating 
along a chemokine gradient247.  Thus, it is possible that the amoeboid morphology seen in 
the microglia represents cells that are trying to move towards infected neurons. Regardless 
of the activation status of the amoeboid microglia, it is apparent that at least some of 
microglia that are incubated with the virally-infected neurons trend toward a unique 
morphology.   
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            Figure 20 
          
Figure 20: Neuron-microglia co-culture and treatment of NSPCs with conditioned medium. (A) CD46+ 
primary neurons were cultured in poly-D-lysine coated plates. The neurons were infected with MV 
(1MOI). Microglia were co-cultured with the neurons and the conditioned medium was used to treat 
NSPCs grown on poly-D-lysine/laminin coated plates. (B) Timeline of co-culture and NSPC treatment. 
Microglia were cultured as mixed glial cultures. Neurons were cultured separately from E. 15.5 mice 
embryos and infected with MV or left untreated. On Day 11, microglia were shaken and detached from 
mixed glial cultres and co cultured with neurons. NSPCs were separately cultured as neurospheres, 
passaged and cultured as monolayers on Day 14. These cultures received the conditioned medium 
from the co-cultured (refer text for treatment groups). NSPCs were detached by trypsinization and 
processed accordingly.  
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Figure 21 
          
Figure: 21: MV infected CD46+ neurons in vitro.  CD46+ neurons were isolated from cortices dissected 
from E.15.5 embryonic mice were cultured on poly-D-lysine coated coverslips in Neurobasal medium 
(NBM). On DIV3, the cells were infected with 1 MOI of MV (right) or left untreated (left). Four days 
post-infection, the coverslips were collected and the cells were fixed and stained for neuronal marker 
(MAP2, green) and measles virus matrix and hemagglutinin proteins (red).  Cell nuclei were stained 
with Hoechst (blue). Both cell body and processes were observed to be infected with MV. Scale bar: 
50 μm.  
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Figure 22 
 
Figure: 22: Microglia in MV-infected co-cultures demonstrate changes in morphology.  CD46+ neurons 
were isolated and cultured (250,000 cells/well) as described previously. On DIV3, the cells were 
infected with 1 MOI of MV or left untreated.  Four days post-infection, microglia (25,000 cells/well) 
were purified from mixed glial cultures and co-cultured with MV-infected (right) or uninfected neurons 
(left). (Cell nuclei were stained with Hoechst (blue). Four days-post co-culturing, the coverslips were 
fixed and stained for MV (matrix and hemagglutinin proteins, red), neuronal marker (NeuN, green), 
and microglial marker (IBA1, purple). Microglia in MV-infected cultures were observed to have a more 
amoeboid shape, whereas those in the uninfected cultured were small without and circular. Scale bar: 
50 μm.  
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III. Conditioned medium from MV-infected neuron-microglia co-culture increases NSPC 
differentiation 
To understand the effect of factors released from neuron-microglia co-cultures on 
NSPC differentiation, conditioned medium from the co-cultures was transferred to NSPC 
cultures, which were then allowed to differentiate for 4 days. NSPCs were treated with 
conditioned medium from the following groups:  
a. Uninfected neurons only- Group I 
b. MV-infected neurons without microglia- Group II 
c. Uninfected neurons with microglia- Group III 
d. MV-infected neurons with microglia- Group IV 
The first two groups would control for effects from factors released from uninfected 
neurons alone and from MV-infected neurons. The third group accounts for factors released 
due to co-culturing of uninfected neurons with the microglia. Finally, Group IV would 
demonstrate the effects of mediators released due to interactions between microglia and 
MV-infected neurons.  
NSPCs were cultured in the conditioned medium and collected at the end of treatment 
period (4 DIV). NSPC cultures were stained with neural markers for NSPCs (nestin and 
SOX2) to determine effects on the NSPC pool, or with DCX,  III tubulin (immature and 
mature neurons) and GFAP (mature glia) to measure differentiation by flow cytometry. 
Representative graphs of cell count versus fluorescence intensity for each marker (Figure 
23A-E, quantification Figure 24A-E) are shown.  DCX+ cells increased in the NSPCs 
treated with media from the Group IV compared to all three controls (Figure 23, 24A). 
The percentage of DCX+ cells in each group is listed in (Table 6). A representative ICC 
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image of NSPCs treated with conditioned medium form group II and IV is shown in Figure 
25. This data indicates that media from Group IV leads to an increase in differentiation into 
the neuronal lineage. No statistically significant changes were observed with the more 
mature neural markers: III tubulin and GFAP (Figure 23, 24B and C). Longer incubation 
with the conditioned media would have allowed for some of the DCX+ cells to transition 
into more mature neurons (III tubulin).  The magnitude of change in the number of cells 
expressing III tubulin and GFAP between groups I-II and groups III-IV was similar (~2-
fold). This suggested that MV-infected neurons themselves may be releasing factors that 
resulted in increased neuronal and glial differentiation.  
No significant differences were observed in the pool of nestin+ NSPCs (Figure 23, 
24D). On the other hand, a significant decrease was seen in SOX2 expression in 
comparison to groups I, II and III (Figure 23, 24E; 92.0%2.3 v/s 76.7%4.7; p<0.05). 
These results may indicate that NSPC differentiation increases when NSPCs are treated 
with conditioned medium from MV-infected neurons co-cultured with microglia. In 
NSPCs, nestin expression is regulated by SOX2 which acts as a transcription factor248. 
Therefore, the changes in SOX2 expression may preceded changes in Nestin expression. 
Additionally, we observed was with the morphology of the NSPCs (Figure 26). Nestin 
staining during the differentiation process revealed that NSPCs that were treated with 
conditioned medium from Groups III and IV (with microglia in co-culture), had a distinct 
morphology. These cells had a more rounded shape in comparison to NSPCs treated with 
group I and II conditioned medium, which had thin cellular processes that were elongated 
from end-to-end. Whether these changes in morphology are associated with differentiation, 
changes in cytoskeletal structure, or both is still to be determined. To determine whether 
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differentiation was associated with changes in levels of protein expression, mean 
fluorescence intensity (MFI) was used as a measure neural marker expression. We did not 
observe any change in the protein expression corresponding to those seen with cell numbers 
seen in Figure 24. In fact, GFAP expression was reduced in groups II, III and IV. For DCX, 
even though more cells were being formed in Group IV, there was no change in the net 
protein expression within the groups. For GFAP, group I which showed lowest 
differentiation had highest GFAP expression as compared to other groups. Astrocytes may 
increase GFAP expression when stressed or activated249. Therefore, it could be possible 
that in presence of conditioned medium with MV infection and microglia co-culture, there 
may be increased GFAP differentiation but lower stress/activation.  
 
IV. Media from MV-infected neuron-microglia co-culture causes a modest increase in 
DNA synthesis 
To determine whether the neuron-microglia supernatants affect NSPC 
proliferation, we measured BrdU incorporation in treated NSPCs. BrdU incorporation is 
an indicator of newly synthesized DNA and can be used to track cell cycle progression. 
NSPCs were cultured in the conditioned medium as with the differentiation experiments. 
Four days post-treatment with conditioned medium, the cells were pulsed with 25 M 
BrdU for 90 minutes at 37C. The cells were collected and BrdU incorporation was 
measured using flow cytometry. BrdU incorporation was increased in group IV compared 
to group I (Figure 23, 24F).  However, group IV did not significantly differ when 
compared to groups II and III. Therefore, more cells were in the S-phase in group IV as 
compared to group I.  This indicated that MV infection or microglia alone did not affect 
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NSPC proliferation. There had to be an interaction between the two to have a significant 
effect on NSPCs proliferation.  
Changes in the cell cycle progression was also measured by counterstaining the 
NSPCs with 7-AAD along with BrdU staining. Cells in S, G0/G1 and G2/M phases of the 
cell cycle were measured by analyzing the cells graphed for BrDU v/s 7-AAD (Figure 
23G, 24 F, G, H). We did not observe any changes in the cell cycle progression. There 
were no significant differences observed in the G0/G1 or G2/M phases with any of the 
groups (Figure 24G and H).   
 
       Table 6 
Conditioned medium treatment 
 
DCX+cells 
(%Live cells) 
Group I 19.400.948 
Group II 19.290.986 
Group III 19.641.122 
Group IV 24.131.452 
                      Table 6: Summary of DCX+ cells post-conditioned medium treatment 
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Figure 23 
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Figure 23: Measurement of changes in NSPC differentiation and cell cycle progression. NSPCs were 
treated with conditioned medium from co-cultures on DIV1. Treatment groups were; uninfected 
without microglia (group I), MV-infected without microglia (group II), uninfected with microglia (group 
III)., and MV-infected with microglia (group IV). Cells from each treatment groups were detached from 
culture plates, fixed, permeabilized, and stained for (A) DCX, (B) III tubulin, (C) GFAP, (D) Nestin, 
(ESOX2 and passed through the flow cytometer. Live cells were first gated to exclude debris. Cell Cycle 
progression was measured by subjecting the NSPC cultures from different groups to the BrdU assay.  
(F) The number of BrdU+ NSPCs (S-phase) were graphed separately as number of cells v/s fluorescence 
intensity (A.U). (G) Representative graphs of NSPCs form groups I, II, III and IV in G0/G1, S and G2/M 
phases of the cell cycle prepared by measuring BrdU incorporation v/s 7-AAD staining.  
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         Figure 24 
 
Figure 24: Enhanced NSPCs differentiation and BrdU incorporation upon treatment with conditioned 
medium.  (A-E) Percentage of live cells positive for (A) DCX, (B) III tubulin, (C) GFAP, (D) Nestin (E) 
SOX2, were graphed for each of the treatment groups. Data was presented as meanSEM for each of 
the treatment groups and analyzed using a two-way ANOVA with Holm-Sidak multiple comparison 
test; n=3, * p<0.05. Cells were process as for neural markers and average percentageSEM of cells in 
the (F) S phase (BrdU+), (G) G0/G1 phase (H) G2/M phase, were graphed analyzed using two-way 
ANOVA with Holm-Sidak multiple comparison test; *p<0.05 
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Figure 25 
 
Figure 25: Reduced GFAP expression in NSPCs post conditioned medium treatment. (A-E) Mean 
fluorescence intensities (MFI) in arbitrary units were graphed for each of the treatment groups (A.U) 
for (A) DCX, (B) III tubulin, (C) GFAP, (D) Nestin (E) SOX2. Data was presented as meanSEM for each 
of the treatment groups and analyzed using a two-way ANOVA with Holm-Sidak multiple comparison 
test; n=3, * p<0.05.  
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Figure 26
 
Figure 26: Enhanced neuronal differentiation in response to treatment with MV-infected neurons co-
cultured with microglia. Representative ICC images of NSPCs treated with conditioned medium from 
groups III (left) and IV (right). NSPCs were allowed to differentiate as monolayer cultures and stained 
for Nestin (red) and DCX (green). Treatment with conditioned medium from group IV had higher DCX+ 
cells as compared to group III. Scale bar 50 m.  
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V. Discussion 
Microglia are an important source of cytokines during viral infections and play a 
major part in the host defense against viruses in the brain. They also play an important role 
in normal brain development, where they are responsible for controlling NSPCs numbers 
and pruning of neuronal networks. NSPCs may be infected by the viruses themselves which 
may cause changes in their survival and/or changes in differentiation. However, in addition 
to infections, NSPCs may also be affected by inflammatory mediators released from 
immune cells and infected cells.  We hypothesized that microglial cells would affect 
NSPCs during a neurotropic viral infection through release of soluble mediators. To 
address this question, we have used a co-culture system of MV-infected neurons and 
microglia. The viral infection is restricted to the neurons and microglial cells are not 
infected. The inflammatory mediators released from both the neurons and microglia can 
then be applied to NSPC cultures to study how proliferation and differentiation of the 
NPSCs is affected.  
Treatment with conditioned medium from MV-infected neurons/microglia cultures 
increased the immature neuronal cell pool (DCX+ cells). However, the same was not 
observed for mature neural markers, III tubulin (neurons) as well as GFAP (astrocytes). 
One reason for this effect could be that the time point at which the cells were collected may 
have not allowed for full differentiation and expression of more mature neural markers. At 
basal levels (uninfected neurons-No microglia group), approximately 2% of the total cells 
in the NSPC cultures express these markers, suggesting a low basal level of differentiation 
in the cultures.   
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BrdU incorporation is a measure of DNA synthesis that can represent cells that are 
in the S-phase of the cell cycle or cells that are actively repairing damaged DNA. Notably, 
there was increased BrdU incorporation when NSPCs were treated conditioned medium 
from MV-infected neurons co-cultured with microglia (group IV). One explanation for this 
could be that NSPCs, even though differentiating, may not be terminally differentiated. 
There may be in increase in the amounts of committed precursors that may still be in 
cooperating BrdU. This can be corroborated by the increase in the number of DCX+ cells 
in this group. If these DCX+ neurons accounted for an increase in BrdU incorporation 
could be confirmed by double staining for DCX and BrdU using ICC. Also, it is important 
to note that there was no significant increase in the numbers of terminally differentiated 
neural cells (neurons or astrocytes).  Longer differentiation time points may be necessary 
to determine if the there are any changes in the glial and neuronal differentiation. Moreover, 
elucidation of committed glial precursor cell numbers is needed to determine if early glial 
commitment is affected.  
Another important question would be to determine which inflammatory mediators 
in the conditioned medium mediate the effects seen on NSPCs. In chapter 3, we have 
demonstrated that IFN, an important proinflammatory cytokine released during viral 
infections, reduced NSPC proliferation. Here, we observe an increase in BrdU 
incorporation, which suggests that IFN may not be expressed by the microglia or that 
other cytokines with a proliferative effect may dominate.  Moreover, the role of other 
cytokines and chemokine such as IL-6, IL-1, and TNF- also needs to be elucidated.  
Yukari, et al studied the physiological roles of microglia in the early post-natal brain250. 
They observed that activated microglia were present in the SVZ of the rat brain from P1 to 
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P10. When the activation of these microglia was attenuated, the expression of 
proinflammatory cytokines (IL-1, IL-6, TNF-, and IFN) was reduced.  Attenuation of 
microglial activation also inhibited the number of NSPC and neurons in vivo and in vitro. 
These studies showed that a basal level of microglial activation brings about normal CNS 
development.   In CNS diseases, however, how enhanced microglial activation affects the 
normal activity of NPSCs is unclear. Butovsky, et al suggest that the type of stimuli that 
activate the microglia may determine the ultimate effects on NSPC activity. They observed 
that co-culture of microglia activated by IL-4 or low levels of IFN with NSPCs increases 
neuronal differentiation, as we have observed in our cultures. On the other hand, microglia 
activated by the endotoxin LPS reduced neuronal differentiation251. Moreover, a recent 
study by Choi, et al demonstrated that differentially activated microglia (LPS- versus IL-
4- treated) had distinct effects on NSPC proliferation and differentiation in organotypic 
cultures derived from ischemic mouse brain252. Conditioned medium from IL-4-treated 
microglia increased proliferation in the SVZ-NSPCs and increased neurogenesis 
(DCX+/BrdU+ cells). Moreover, the effects were mediated by IL-10 and TGF secreted 
from activated microglial cells. This study suggests that during CNS diseases, NSPCs 
respond to activated microglia by modulating production of new neurons, and the 
activating signal to the microglia determines the effects on NSPCs. In a study by Chucair-
Elliott et al, microglia prevented a decrease neuronal differentiation caused by HSV-1 
infection, either through transfer of supernatants from microglia-NSPC co-cultures or 
through direct co-culture with the microglia54. This finding highlights the fact that 
microglia may not only induce protective effects though direct contact with NSPCs, but 
also though factors released as a result of their interaction with other neural cell types. 
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Ovanesov et al, also examined the mechanisms of microglia activation in BDV-infected 
rat brains in a neuron-microglia co-culture. They observed that microglia are activated by 
conditioned medium from BDV-infected neurons, and released IL-6 in response. This 
reinforces the fact that microglia interact with injured neurons to stimulate cytokine release, 
which may affect NSPC activity. 
Here, we have developed an in vitro model system to analyze the how microglia 
react to virally-infected neurons, and how subsequent release of factors impact on the 
responding NSPCs. We observed increased neuronal differentiation when NSPCs are 
exposed to conditioned medium from microglia co-cultured with MV-infected neurons. 
However, the cytokine profile release as a result of cross-talk between MV-infected 
neurons and microglia needs to be evaluated. Moreover, in this model, the role of other 
immune cells including infiltrating peripheral macrophages, T-cells (CD4+ and CD8+) is 
not addressed.  Nevertheless, the observations that we define in vitro can be ultimately 
modeled in vivo in the CD46+ model through inhibition of microglial activation and 
through knockdown of specific cytokines that are produced by the activated microglia.  
Together, these studies will help to define how NSPCs respond to the inflammatory 
environment induced by an infection.   
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Figure 27 
            
Figure 27: Changes in NSPC morphology upon treatment with conditioned medium.  NSPCs were grown 
as monolayers on poly-D-lysine/laminin coated coverslips. Cells were treated with conditioned 
medium form (A) Uninfected neurons (group I) (B) MV-infected neurons without microglia (group II) 
(C) Uninfected neurons with microglia (group III) (D) MV-infected neurons with microglia (group IV).  
Four days-post conditioned medium treatment, coverslips were fixed and stained for Nestin (green) 
and nuclear stain, Hoechst (blue).  Cells treated with conditioned medium that were co-cultured with 
microglia (groups (III and IV) showed altered morphology with thicker cellular processes as compared 
to those that were treated with conditioned medium from neurons that were not co-cultured with 
microglia (groups I and II). Scale bar= 50 m.  
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Conclusion 
Viral infections of the central nervous system are associated with devastating 
neurological consequences during brain development especially in the prenatal and 
neonatal stages. The aim of my thesis was to define how neural stem/progenitor cells 
(NSPCs) respond to key inflammatory mediators that are often expressed during viral 
infections.  In addition, we wanted to elucidate whether immune-mediated changes in 
NSPC activity would contribute to protective or pathological outcome in the brain. We 
found that IFN, a cytokine critical for clearance of many virus from the CNS, also 
interferes with NSPC activity. Treatment of NSPCs with IFN decreased NSPC cell cycle 
progression by multiple cellular and molecular measures. We discovered a new mechanism 
for IFN-mediated control of NSPC proliferation involving restriction of the cell cycle at 
the late stage of G1/S transition through decreased expression of the Cyclin E/CDK2 
complex.  Moreover, to our knowledge, we are the first to report IFN-mediated in site-
specific phosphorylation of the retinoblastoma protein, which plays a central role in cell 
cycle progression.  The effects of IFN on the proliferation and cell cycle regulatory 
proteins were dependent upon STAT1, which contrasts with CNS neurons that respond to 
IFN through STAT1-independent mechanisms.  These results suggest that IFN impedes 
NSPC proliferation and growth, but that the effects of IFN in the brain are unique to each 
cell neural cell type.   
During a viral infection, both infected and uninfected neural cells will respond to 
the inflammatory environment in an attempt to limit viral spread.  The ultimate effects of 
both responses may contribute to either pathology or protection from CNS damage. Our 
data demonstrate that uninfected NSPCs respond to IFN with decreased proliferation. This 
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cytostatic response of NSPCs could have both positive and negative effects for the host. If 
the NSPCs are targets of the virus, inhibiting proliferation could provide a beneficial effect 
to the host by slowing viral replication in the infected cells.  In contrast, inhibition of NSPC 
growth could have a negative impact on brain development by limiting the pool of new 
neurons during critical stages of neurogenesis.  If the virus displays tropism for immature 
neurons, inhibiting NSPC differentiation could further limit viral spread by reducing 
newly-differentiated neurons.  Thus, the infected brain tissue must balance the benefits of 
preventing continued viral spread with the potential deficits to development of the brain.  
We did not observe high levels of IFN-induced apoptosis in NSPCs, despite evidence in 
other cell types for more extensive cell death. This finding suggests that decreased 
proliferation is not associated with programmed cell death.  
Our model focused on the interactions between inflammatory mediators and 
uninfected NSPCs that may reside in the vicinity of the immune response.  Ultimately, the 
effect of IFN on infected NSPCs may depend on the virus-induced changes in cellular 
proliferation mechanisms. The purpose of a virus infecting a host cell is to produce 
functional progeny that may then infect other cells and allow for viral persistence in the 
host.  Depending on the type of virus, the host cell cycle may be modified by viral proteins 
to allow for increased persistence or survival of the virus253. For example,  HIV arrests 
cells in the G2-phase, which allows for an optimal environment for viral protein production 
for this virus254. On the other hand, MV induces a cell cycle arrest in the G0 phase255. 
Viruses such as the human papilloma virus (HPV) induce S-phase entry of infected cells 
in order to create an environment that is favorable for rapid viral replication256.   Given the 
pluripotent nature of IFN, a variety of anti-viral mechanisms are possible, which may be 
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partially dependent on the effects the virus has on the cell cycle.  For those viruses that 
increase cell proliferation, IFN may counteract that effect by decreasing NSPC 
proliferation. However, with those viruses that favor cell cycle arrest, IFN may act through 
entirely different anti-viral pathways, such as activation of RNA degrading enzymes or 
through heightened sensitivity to Type I interferons.  Regardless of whether the NSPCs are 
targets of a particular virus, the response of the NSPCs to the anti-viral immune response 
has the potential to severely alter brain development. 
In addition to IFN, the cytokine milieu consists of a number of other inflammatory 
factors which that may affect NSPCs. During viral infections, there are several sources of 
the cytokines and trophic factors, including innate and adaptive immune cells, glial cells 
and even infected neurons.   Among the immune cells that can respond to viruses, 
microglial cells are the first immune cell to encounter a virus in the brain.  Microglia play 
an important role in the embryonic brain by contributing to CNS development by regulating 
the number of NSPCs and aiding the formation of neural networks250.  In neurotropic viral 
infections, activated microglia not only play a major role recruitment of immune cells 
during CNS pathology, but also function as effectors by secreting factors that may affect 
NSPC activity257. Ongoing studies on the interaction between activated microglia and 
NSPCs show that microglia can direct NSPC proliferation and differentiation. Many 
groups have suggested that activated microglia may increase NSPC proliferation and 
induce their differentiation during neurodegenerative conditions258,259. Because microglia 
are activated in response to viral infections in our CD46 model and others, we wanted to 
study how microglia that are responding to infected neurons could influence NSPC activity. 
Using the CD46 model, we selectively infected neurons with MV, sparing the microglia 
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and NSPCs from infection. To study the effects of the interaction between infected neurons 
and microglia on NSPCs, we developed a unique co-culture system of MV-infected CD46+ 
neurons and microglia, where media from the neuron/microglia cultures are incubated with 
NSPCs.   We hypothesized that MV-infected neurons would activate microglia in vitro and 
immune mediators released from co-cultured cells would increase NSPC differentiation. 
Two aspects of NSPC activity are considered important with respect to their role in CNS 
development and response to CNS pathology, namely, NSPC proliferation and 
differentiation into neural lineages. We observed a modest increase in the number of 
NSPCs entering the S-phase when treated with conditioned medium from MV-infected 
neurons/microglia co-cultures in comparison to controls. In addition, NSPCs treated with 
MV-infected neurons/microglial conditioned medium demonstrated greater neuronal 
differentiation into immature neurons and reduced SOX2 expression, suggesting that the 
‘stemness’ of the NSPCs was declining and were becoming more differentiated.  
Differentiation into mature astrocytic (GFAP+) and neuronal lineages (III-tubulin) was 
found to be generally low in all treatment conditions, which may reflect the time point at 
which differentiation was measured (4 DIV). The neuronal and microglial mediators that 
control NSPC proliferation and differentiation are an open question.  Determining the 
cytokines and chemokines released from the microglia would add light on the type of 
microglial activation that may occur in response to neurotropic infection. 
In this study, I have demonstrated that IFN may decrease NSPC proliferation, 
increase astrocytic differentiation and decrease neuronal differentiation. Viruses prefer 
actively proliferating cells to multiply. NSPCs, which also actively proliferate may are 
attractive targets for many of these viruses, which may affect NSPC survival an 
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differentiation and ultimately lead to neurodevelopmental deficits. The IFN-mediated 
decrease in NSPC proliferation and neuronal differentiation could potentially reduce NSPC 
from being attractive targets for viral infection. Neurons are non-renewable entities in the 
CNS and many viruses use them for spread and reservoirs during dormant phases. 
Therefore, reduced neuronal differentiation could reduce the cells available for viral spread 
and latency. On the other hand, cytokines released form potential changes in activation 
state of microglial cells in response to a neurotropic viral infection caused an increase in 
neuronal differentiation without changes in NSPC proliferation (Figure 27A). These 
results suggest that NSPC response to cytokines depends upon the types of cytokines acting 
on them. Infected neurons may produce chemokines such as CX3CL1260. Microglial cells 
express CX3CR1, the receptor that binds the ligand CX3CL1261. Upon CX3CL1 binding, 
microglial cells reduce production of pro-inflammatory cytokines such as IL-, IL-6, and 
TNF262,263. Moreover, CX3CL1 mediates increased expression of TGF-, which in turn 
may mediate neuronal differentiation in NSPCs264,265.  Considering the contrasting effects 
that we observe between microglia and IFN alone, one could predict that IFN might not 
be part of the cytokine milieu released by microglia during neurotropic viral infections. 
However, in vivo other immune cells such as T-cells and NK-cells which are sources of 
IFN may also affect NSPC activity. Moreover, these cells may affect the activation state 
of microglia which will also affect NSPC activity. Therefore, in vivo studies are needed to 
understand the effects of different parts of immune system on NSPC activity, and the 
ultimate contribution protection or pathology in viral infection. 
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Figure 28 
 
Figure 28: The immune response to neurotropic viral infections mediates changes in NSPC activity. 
Microglia may respond to cytokines and chemokines such as CX3CL1 released from MV-infected 
neurons. In response to CX3CL1 stimulation, microglia upregulate expression of growth factors such 
as TGF- and downregulate proinflammatory cytokines like IL-1, IL-6 and TNF-. Moreover, TGF- 
causes neuronal differentiation in NSPCs. Therefore, results from our data indicate that neuronal 
differentiation observed in NSPCs treated with conditioned medium from MV-infected neurons co-
cultured with microglia could be, in part, due to increased TGF- section and decreased 
proinflammatory cytokine section from microglia. Other immune cells, such as T-cells and NK-cells, are 
major sources of IFN, which decrease NSPC proliferation through reduced expression of cyclin E/CDK2 
complexes and inhibition of cell cycle progression. Moreover, microglia also respond to cytokine 
stimuli from these immune cells, particularly to IFN, which may drive the microglia into a more 
protective phenotype. Therefore, decreased NSPC proliferation would make NSPCs less attractive 
targets for viruses that prefer infecting actively proliferating cells. Increased neuronal differentiation 
would possibly replace the pool of neurons that may be lost or damaged due to the infection. However, 
whether increased neuronal differentiation also leads to functional integration or alterations in 
behavior or learning needs to be investigated. 
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In this study, my goal was to understand how anti-viral immunity may affect neural 
development, specifically focusing on the effects of soluble inflammatory mediators. 
NSPCs, being the only pluripotent cells in the CNS, are an especially important cell type 
when considering the various neurodevelopmental disorders that can result from viral 
infections.  We defined an IFN-mediated mechanisms of NSPC cell cycle control that 
demonstrates that part of the anti-viral immune response in the brain could include 
prohibiting NSPC growth.  Moreover, using a neuron restricted MV-infections model, we 
determined that inflammatory mediators released from infected neurons, and the 
responding microglia, can steer differentiation of the uninfected NSPCs.  
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